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Abstract 
Tuberculosis (TB), caused by Mycobacterium tuberculosis, has been treated with the same 
arsenal of antibiotics since the 1970’s; and with an estimated one third of the world’s 
population latently infected at the moment, new regimens are sorely needed. Treatment 
remains lengthy and difficult, and inappropriate dosing or administration of drugs as well as 
patient non-compliance is contributing to the rising threat of multi-, extensively- and now 
totally- drug resistant TB. Should further expansion of resistant strains become a reality it 
would render our current antibiotics useless. To address the need for new therapies, this 
thesis explores both in vitro and in vivo approaches using a novel nanoparticle-based efflux 
pump inhibitor-antibiotic combination treatment. Bacterial efflux pumps (EPs) are inducible 
membrane-based transporters that can reduce intracellular concentrations of drugs, which 
leaves open a window for the development of permanent genetic drug resistance. By blocking 
these EPs with EP inhibitors such as thioridazine (TZ), while simultaneously treating with 
one of the most efficient anti-TB drugs, rifampicin (RIF), we predicted a synergistic effect 
likely caused by an increased intracellular concentration of both drugs in the bacteria. The 
first aim of this study was to develop a protocol for the encapsulation of TZ in polymeric 
poly(lactic-co-glycolic) acid nanoparticles (PLGA NPs). Our group has previously 
established that PLGA NPs with RIF localize in the same cells as the bacteria, and improve 
therapy both in vitro and in vivo relative to free drug. Slow release from these particles and 
facilitated macrophage uptake could potentially lead to treatment that can be administered 
less frequently in a more targeted and consequently less toxic manner. This may be especially 
beneficial in the case of TZ, which is associated with serious dose-dependent cardiotoxicity. 
The second aim of the study was therefore to determine if the encapsulated form of TZ was 
less toxic than the free form. The third aim of this study was to explore the possible role of 
TZ as a potentiator of traditional anti-TB therapy. We found that encapsulating TZ in PLGA 
NPs reduced TZ toxicity, and had a synergistic effect when administered together with RIF. 
This was the case both in vitro, in primary murine macrophages infected with Mycobacterium 
bovis BCG, and in vivo, in the zebrafish model infected with Mycobacterium marinum. 
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1 Introduction 
1.1 Tuberculosis: past and present 
1.1.1 Historical context 
Tuberculosis (TB) is an ancient disease whose causative agent, Mycobacterium 
tuberculosis (M. tb), has plagued its human host throughout known history [1]. M. tb and 
related mycobacterial species have been linked to a common progenitor species thought to 
have originated three million years ago. Extant representatives of this progenitor species have 
been found in East Africa, where they still cause human TB, suggesting that it is one of 
humankind’s oldest infectious diseases [2]. Various strains of the bacteria from different 
geographical areas have also been traced back to East Africa, which implies that this is where 
the ancestral pathogen first emerged. This means that TB and modern humans likely 
originated in the same place, and it follows that the disease may have affected pre-human 
hominids as they evolved together [2, 3]. 
In 1882, Robert Koch was the first to actually link the M. tb pathogen to TB disease 
when he identified the rod-shaped bacterium in material extracted from stained human 
tubercules, the characteristic lesions formed in infected tissue [4]. Following Koch’s 
discovery, attempts were made to develop a TB vaccine during the early 1900s by Calmette 
and Guérin at the Pasteur institute in France [1, 5]. Starting with a strain of the closely related 
Mycobacterium bovis in 1908, they spent 11 years attenuating the pathogen by serial passage, 
even sub-culturing throughout the outbreak of the First World War. The new vaccine was 
named Bacille Calmette-Guérin (BCG) after its creators and was first tested in humans in 
1921. Mass production and distribution of the vaccine soon followed, especially peaking 
during the outbreak of TB in Asia and Europe that followed the Second World War [6]. It 
was later found that the attenuation of the bacilli was due to loss of several segments of 
DNA, notably a crucial virulence determinant coding for a secretion system (ESX-1) [7, 8]. 
 
1.1.2 Tuberculosis combination chemotherapy and vaccination 
Antibiotic treatment for TB first became available with the introduction of 
streptomycin (SM) in 1946 [9]. However, the first clinical trial against pulmonary TB already 
hinted at the presence of SM-resistant bacilli [10]. To circumvent this development of 
resistance, treatment of bacterial diseases with a combination of two or more independently 
acting antimicrobial agents was introduced in 1913. During the fifties, several studies 
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confirmed that this multidrug treatment was less likely to result in resistance and therefore 
led to more efficient therapy [11]. By the 1970’s isoniazid (INH), rifampicin (RIF) and 
pyrazinamide (PZA), and later ethambutol (EMB), were established as novel anti-tubercular 
drugs and were soon incorporated into the standard regimen. By using combinations of these 
drugs, it was found that treatment time could be shortened from twelve to six months, while 
reducing the rate of relapse from 29 percent to 3-8 percent [9]. 
According to the standard treatment recommended by the World Health Organization 
(WHO) today, first-time TB patients who have not been exposed to drug-resistant strains are 
treated in two phases that together last for a total minimum of six months. The initial phase 
consists of two months with daily administrations of the first line drugs INH, RIF, PZA, and 
EMB. This is followed by a four-month continuation phase comprising just INH and RIF 
[12]. In the case of drug resistance or intolerance to any of the first line drugs, a group of 
second-line drugs is used, which are more expensive, less efficient and more toxic. These 
include fluoroquinolones and injectable antimicrobials (capreomycin, kanamycin, and 
amikacin) [13]. 
The Mycobacterium bovis BCG vaccine continues to be the only vaccine available 
against TB, despite ongoing efforts to develop novel strategies [14]. In its more than 80 years 
of use, BCG has been delivered to more people than any other vaccine. Unfortunately, while 
it does protect to an appreciable degree against childhood TB (miliary and meningeal), it is 
not nearly as effective at protecting adults from pulmonary TB, the most prevalent form of 
TB today [15]. 
  
1.1.3 Current prevalence 
M. tb infections can either persist in an active, infectious state associated with the 
clinical symptoms of TB, or a latent state where patients are asymptomatic and non-
infectious. According to the WHO, in 2012 it was estimated that 12 million people had active 
TB, whereas one third of the world’s population had latent TB [16]. Of these latently infected 
individuals, 5-20% will go on to develop an active, infectious form of the disease during their 
lifetime [16]. This progression to active disease is fueled by several circumstances, among 
others immunosuppression due to co-infection with HIV, malnutrition, diabetes or alcohol 
abuse. Although drug-sensitive TB is considered curable, in 2012 a staggering 8.6 million 
people contracted active TB, and 1.3 million died from the disease, a high proportion of 
which were HIV positive. Eastern Europe, Africa and South-East Asia are bearing the highest 
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burden of the disease. Among these, India and China stand out with the two highest incidence 
rates, while TB co-infection with HIV was highest in the African region [16]. 
 
1.2 Routes of infection and dissemination 
1.2.1 Initial infection 
M. tb is an intracellular pathogen that usually spreads from person to person by 
coughing or sneezing, resulting in airborne droplets that contain the bacteria. When these 
droplets are inhaled, the bacteria enter the lungs where they are ingested by alveolar 
macrophages [17]. Unlike extracellular pathogens, M. tb has developed several mechanisms 
to ensure macrophage uptake by phagocytosis, including non-traditional mechanisms to 
induce opsonization by complement factors leading to uptake by complement receptors [18]. 
M. tb can also be taken up following binding to mannose receptors, CD14 binding, scavenger 
receptors or Fcγ receptors [18]. Regardless of the receptors involved, phagocytosis leads to 
the internalization of M. tb in a membrane-bound phagosome. Phagosomes are normally able 
to interact with the endocytic pathway where they mature and fuse with lysosomes, causing a 
drop in pH which aids in degradation of the phago-lysosomal content [19]. To avoid this fate, 
M. tb is able to block phagosome maturation by arresting phago-lysosome fusion [19, 20]; the 
bacteria then remain in a phagosome with a pH of 6.4 [21]. Sheltered in this intracellular 
niche, the bacteria are able to exploit the host cells nutrients, such as iron from transferrin 
[22]. Before macrophages are activated by the adaptive immune system, they are often able 
to contain, but not clear the infection, allowing M. tb to persist intracellularly [23]. In most 
cases the bacteria can enter a state of prolonged dormancy, which is what characterizes a 
latent infection. Hidden inside an infected macrophage they can be protected from the rest of 
the immune system by blocking host antigen presentation and modulating cytokine 
production [24]. On the other hand, if the bacteria instead proliferate inside the macrophage, 
they can spread and cause the active, infectious form of TB [25]. Infected macrophages can 
then recruit healthy macrophages, which can in turn be infected when they encounter 
extracellular bacteria at the disease site. This starts the process of granuloma formation [26].  
 
1.2.2 The granuloma 
Often referred to as “the hallmark structure of TB”, the granuloma plays an important 
role in the balance between eradication and advancement of the disease. This tightly packed 
structure is made up of a variety of immune cells, which are clustered together in order to 
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contain a central core of infected and necrotic cells as well as extracellular bacteria released 
from dying macrophages [27]. Granuloma formation is initiated by infected alveolar 
macrophages, which provoke an inflammatory response capable of recruiting additional 
immune cells; including more macrophages, neutrophils, monocytes and dendritic cells [28]. 
Activated dendritic cells then drain to the lymph node [29, 30] and in turn recruit B cells and 
T cells which also aggregate at the infection site, aiding in bacterial killing and macrophage 
activation [28]. With the help of the adaptive immune system, macrophages mature, increase 
their microbicidal capacity and change their morphology, becoming larger with ruffled cell 
membranes [27]. Sustained release of the cytokine Tumor Necrosis Factor (TNF) by 
macrophages and T cells play a major role in recruitment of cells and granuloma maintenance 
[28, 31]. In addition to walling off bacterial infection, the granuloma creates a local 
environment tuned to restricting potentially harmful inflammation, as well as facilitating 
interaction between the adaptive and innate immune system [31].  
 
1.2.3 Transmission 
Despite the efforts of both the innate and adaptive immune cells to clear the M. tb 
infection, some macrophages will become overwhelmed and undergo necrosis. This leads to 
the formation of a characteristic necrotic core known as the caseum. The caseum can 
disintegrate, or “liquefy”, providing an excellent medium for the extracellular growth of 
bacteria released from dying macrophages. Necrotic tissue surrounding the granuloma can 
rupture, and may subsequently spread the infection to other parts of the lung or release viable 
M. tb into the airways [17]. Subsequent coughing and expulsion of droplets allows the 
mycobacteria an opportunity to escape the lungs and infect other hosts, re-starting the cycle 
of TB [27, 28]. 
 
1.3 The emergence of resistance 
1.3.1 Multi-drug resistant TB  
Although the global mortality rate from TB has fallen by 45% since 1990, the 
emergence of multi-drug resistant TB (MDR-TB) is a growing threat. TB is considered MDR 
when it is resistant to RIF and INH, two of the most potent first line drugs. There were an 
estimated 450,000 new incidences of MDR-TB in 2012, which makes up about 5% of total 
incident TB cases that year. However, of the 1.3 million people that died from TB in 2012, 
13% died from MDR-TB, indicating that MDR-TB is proportionally more lethal than 
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susceptible TB. The majority of these MDR cases were registered in Eastern Europe and 
Asia, notably in India, China and Russia [16]. This emerging drug-resistance has been fueled 
by sub-optimal dosing of antibiotics during treatment, in part caused by failure of health care 
providers to follow and supervise treatment and drug quality according to WHO standards. In 
addition, inappropriate use of antibiotics has been linked to a lack of patient compliance, 
made especially difficult by the long course of treatment which can be expensive, toxic and 
cumbersome [12, 32]. Lastly, granulomas are heterogeneous and difficult to penetrate, which 
can lead to inadequate accumulation of drugs at the disease site [33]. Even if efforts are made 
to reduce the risk of resistance by using combination therapy, sub-lethal doses of these drugs 
can not only allow bacteria to survive, leading to relapse, but also select for resistant bacterial 
genotypes [13]. In addition to the possibility for M. tb to acquire novel genetic resistance 
during treatment, MDR-TB can also be transmitted to new hosts. In fact, up to half of MDR 
cases occur by re-infection of previously untreated patients [34].   
Mycobacteria become genetically resistant as a result of spontaneous mutations that 
interfere with the intended function of the antibiotics. Unlike in other bacterial species, 
acquired resistance is not believed to occur by horizontal gene transfer in M. tb due to its lack 
of plasmids and no documented cases of genomic DNA transfer [35]. Genetic resistance can 
arise through a mutation in the drug target itself, drug-deactivating enzymes or in enzymes 
needed for pro-drug activation [36]. In the case of TB, specific mutations have been 
associated with resistance to all four first-line TB drugs currently in use [35]. Since each 
antibiotic targets a different bacterial mechanism, each one has an independent rate of 
mutation. Even if genetic mutations are rare, a single resistant clone early in infection can 
survive antibiotic treatment and give rise to an entire population of resistant organisms [9]. 
The likelihood that clonal expansion of M. tb in an infected patient will give rise to resistance 
to both the independently-acting drugs INH and RIF has been placed in the range of 10−5 to 
10−4 [37]. This is relatively rare in areas of low TB incidence, but seen in the context of the 
global TB burden, with 8.6 million new active cases in 2012 [16], the emergence of dual 
resistance is feasible [37]. With this in mind, using a combination of more than two different 
antibiotics is necessary to lower this risk and more efficiently clear the infection [38]. 
  
1.3.2 Extensively and totally drug-resistant TB 
When bacteria turn MDR and become resistant to any of the first-line drugs, patients 
are forced to use more toxic and less efficient second- and third-line drugs. These regimens 
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are longer than treatment for standard TB, with a minimum duration of 18-20 months [12]. 
This further increases the risk of patient non-compliance, which is conducive to the 
development of even more resistance. These strains are known as extensively drug-resistant 
(XDR-TB), and have not only lost susceptibility to RIF and INH, but also to at least two 
second-line drugs. By the end of 2012, XDR-TB was reported by 92 countries, making up an 
estimated 9.6% of the MDR cases [16]. To make matters worse, strains of totally drug-
resistant TB (TDR-TB) were reported in Italy in 2007 [39]. These exhibited resistance to the 
full range of our current first- and -second line drug regimens. There have now also been 
reports of TDR-TB in Iran, India and South Africa [40]. With the threat of drug resistance 
rendering our current antibiotics useless, it has been suggested that the “antibiotic era” is over 
[13]. However, even if progress is slow, there are several new classes of drugs currently 
being tested against TB, with 12 currently undergoing clinical trials [41]. 
 
1.4 Phenotypic resistance 
1.4.1 The distinction between genetic and phenotypic resistance 
While some patients respond rapidly to treatment, others have infections which 
appear resistant in that they do not respond to antibiotics, yet the offending bacteria are 
deemed susceptible to therapeutic concentrations in vitro [42]. These bacteria are resistant, 
but they have no genetic mutations in known drug targets [43, 44], implying the existence of 
other, non-genetic, mechanisms of resistance. Here an important distinction is brought to 
light: bacteria that are not considered genetically resistant to antibiotics may still be able to 
persist due to non-genetic mechanisms. This phenomenon is known as phenotypic resistance 
[45]. Until this point in the introduction, the term “resistance” has always been mentioned in 
the context of a genetic change. To be able to distinguish between genetic and phenotypic 
resistance, it is important to present clear definitions of the relevant terminology. 
In the context of this work, resistance to a given drug is defined as the ability of 
bacteria to continue replicating in the face of a determined minimum inhibitory concentration 
(MIC) of drug, which normally prevents such replication. This means that resistance is 
relative to the defined MIC, and that the development of resistance causes an increase in the 
said MIC [36]. Further, such resistance is genetic when it is caused by a change in the DNA 
sequence of the bacterium, as described in section 1.3.1. On the other hand, resistance is 
considered phenotypic when it arises through other, non-genetic mechanisms stimulated by 
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the bacterial environment. Importantly, this kind of increase in MIC as a result of induced 
phenotypic resistance is not heritable, as it would be in a genetically resistant strain. 
 
1.4.2 Phenotypic resistance in dormant cells 
Phenotypic reduction in antibiotic susceptibility was first observed in dormant cells, 
such as those found in latent infections, in the context of many different antibiotics, including 
anti-TB drugs [46, 47]. This is because these drugs usually target mechanisms necessary for 
bacterial growth and proliferation, such as bacterial transcription in the case of RIF, or 
mycolic acid production in the case of INH [47]. In fact, bactericidal activity of INH is 
reduced 1000-fold in non-growing cultures relative to log-phase cultures of M. tb [48]. M. tb 
is an obligate aerobe, but can live in the hypoxic, nutrient-poor environments near the center 
of the granuloma where such a slow-growing state can be induced, helping it to survive 
treatment [49, 50]. These differences in antimicrobial susceptibility cause bacterial killing to 
occur in a biphasic manner. In the initial phase, the antimicrobial in question will rapidly kill 
the metabolically active, susceptible sub-population of bacilli (quantified as the early 
bactericidal activity, EBA, of this drug) [51]. In the second phase, the remaining persistent 
bacteria, which are more difficult to sterilize, necessitate longer treatment in order to get 
complete clearance of the infection [51, 52]. The dormant bacilli remain as a latent infection 
and may lead to relapse if treatment is too short, whereas the replicating bacilli cause the 
symptoms of active disease [52]. 
 
1.4.3 The role of efflux pumps 
Until recently, most models explaining phenotypic resistance in M. tb, and 
consequently efforts to find novel drug targets, have built on the assumption of dormancy 
[53]. In contrast to this, newer models suggest that non-heritable multi-drug phenotypic 
resistance can also be found in actively replicating M. tb, as shown by Adams et al. [53] in 
the zebrafish model. In this study, phenotypic resistance was linked to the action of efflux 
pumps (EPs), which can reduce drug efficacy by limiting its intracellular accumulation [54].  
EPs are highly conserved, membrane-associated transporters important for the active 
removal of toxic substances from the bacterial cell. These pumps can either be very specific 
or recognize a variety of substrates, such as toxins from the environment, including 
antibiotics or host-derived substances, or intracellular metabolites to maintain homeostasis 
[54, 55]. EPs can be found in both eukaryotic cells and a wide variety of bacteria and are 
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subdivided into five distinct families according to their structure and function. These are the 
adenosine-triphosphate-binding cassette (ABC) superfamily, the major facilitator superfamily 
(MFS), the small multidrug resistance (SMR) family, the resistance-nodulation-division 
(RND) family and the multidrug and toxic compound extrusion (MATE) family [54]. Nearly 
50 putative EPs have been identified in M. tb [56]. Furthermore, M. tb knock-outs of EPs 
from the ABC, MFS and SMR families conferred an increase in susceptibility to several 
antibiotics, including the first-line TB drugs RIF, INH and EMB and the second-line TB 
drugs kanamycin and amikacin [57]. In mycobacteria, it has been suggested that up-
regulation of EPs precedes genetic mutations in drug target genes following exposure to anti-
TB drugs [58]. The up-regulation of such pumps works to counter intracellular drug 
accumulation, allowing bacteria to keep replicating in the face of treatment. This continued 
replication opens the possibility for accumulation of mutations, which can lead to permanent 
genetic resistance [58]. 
Constitutively expressed EPs also contribute to intrinsic resistance in mycobacteria 
[59]. Intrinsic resistance is the inherent ability of a given bacterial species to tolerate a given 
antibiotic, for example if it lacks the drug target or produces drug-deactivating enzymes [59]. 
In addition to EP-mediated intrinsic resistance, M. tb has a characteristic waxy cell wall, rich 
in mycolic acid, an uncommon long-chain fatty acid, which makes it largely impermeable to 
antibiotics [60], although some influx of hydrophilic compounds may occur through a limited 
amount of porins [61]. 
As opposed to constitutive expression, the up-regulation of EPs can also be transiently 
induced by the presence of antibiotics. For example, EPs from the ABC, MFS and SMR 
families up-regulate following exposure to all the drugs in the standard TB regimen [62]. One 
study documented the up-regulation of three genes in response to INH, (iniA, B and C), 
where iniA appeared to be a pump component participating in INH removal. Furthermore, an 
M. tb mutant with an iniA deletion showed increased INH susceptibility [63]. In the absence 
of antibiotics, mycobacterial EPs can also be induced by intracellular residence. In a study by 
Adams et al. [53], M. tb and the fish pathogen Mycobacterium marinum (M. m) cultured 
inside macrophages were more resistant to RIF in comparison to bacteria grown 
extracellularly. However, this was no longer the case when M. tb strains lacked a functional 
copy of the EP gene Rv1258c [53], which is up-regulated in the presence of RIF [64]. This 
suggests the involvement of this EP in macrophage-induced resistance [53]. Moreover, 
resistance to RIF in both M. tb and M. m was reduced in the presence of the EP inhibitor 
verapamil. This increase in MIC was non-heritable, implicating phenotypic resistance [53]. 
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In the aforementioned cases, EPs are up-regulated by mechanisms that are 
independent of genetic change, placing them in the phenotypic resistance category. Despite 
this, genetic mutations in EP genes or their regulatory elements, such as promoters or 
transcriptional activators can also lead to EP over-expression [65]. Ultimately, be it by 
genetic or non-genetic mechanisms, increased EP expression leads to acquired resistance in 
organisms that should normally be susceptible to a given drug. Importantly, due to the 
promiscuous nature of some EPs, heightened expression of a single pump can lead to an 
increase in the MIC of several drugs and, accordingly, a MDR phenotype [65]. 
In summary, EPs have been used to explain several facets of resistance to drugs. First 
of all they contribute to intrinsic resistance to antibiotics, together with the mycolic acid cell 
wall. Secondly, they can contribute to phenotypic resistance by means of their non-genetic 
up-regulation, which can either be induced by antibiotics or by macrophage residence. Lastly, 
they can contribute to acquired MDR by means of genetic mutations in regulatory elements 
or the pumps themselves. However, it is possible to block EPs using EP inhibitors, one 
example being verapamil. Thioridazine (TZ) is another such EP inhibitor that has been 
gaining interest as a novel anti-TB drug candidate [53, 66, 67]. 
 
1.5 Efflux pump inhibitors  
1.5.1 Thioridazine  
TZ is a drug that belongs to the phenothiazine group, and has previously been used as 
a neuroleptic for the treatment of Schizophrenia. It has now been removed from the market in 
several countries due to its potentially serious cardiotoxic side-effects, such as prolongation 
of the QT interval [68-70], which is a measurement of the time between ventricular 
depolarization and repolarization. This can lead to an abnormal heartbeat, or ventricular 
arrhythmia, and increases the risk of sudden death [71]. Before the introduction of TZ, the 
first phenothiazine used as a neuroleptic was chlorpromazine (CPZ) [66]. Early on, there 
were anecdotal reports of the positive effect CPZ had on TB infected patients. However, this 
was never seriously pursued due to the emergence of the new antibiotics SM and INH during 
the 1950’s, which were more efficient and less toxic than CPZ [72]. Since then, several 
groups have documented the anti-TB effects of both CPZ and TZ at similar concentrations in 
vitro [72-75]. TZ in particular has been shown to not only inhibit growth of susceptible M. tb, 
but also MDR-strains. In one study, TZ showed 60% inhibition of growth in liquid cultures of 
M. tb at 3 µg/ml and complete inhibition in the range of 12-25 µg/mL [76].  
	  10	  
Unfortunately, a mere concentration of 0.5 µg/ml is considered the maximum safe 
level of TZ in human plasma, which on its own makes it unlikely that this drug can be 
administered safely at therapeutic concentrations [66]. However, an in vitro study from 1992 
by Crowle et al. [72] showed that approximately 8-fold lower doses of CPZ were needed to 
inhibit growth of M. tb inside macrophages in comparison to extracellular M. tb. Although 
there was no direct evidence for this, Crowle suggested that the effect could be due to an 
accumulation of CPZ in lysosomes containing the bacteria, implying that lower, less toxic 
concentrations would be sufficient to reach bactericidal levels in vivo. With this in mind, 
there is some evidence that supports the tendency of phenothiazines to accumulate in 
eukaryotic cells, by binding to membranes [77], including lysosomal membranes, and 
concentrating in tissues, especially liver, lung and kidney [78]. More recently, pre-treating 
macrophages with TZ was found to inhibit intracellular growth of M. tb at 0.1 µg/ml 
regardless of antibiotic susceptibility, when the MIC in culture was found to be as high as 15 
µg/ml [74]. This enhanced effect after phagocytosis has also been seen in other intracellular 
bacteria, such as Staphylococcus aureus [79].  
TZ and related phenothiazines have been shown to inhibit the action of bacterial EPs 
by a fluorometric assay in BCG [80]. TZ also inhibits the expression of several EPs, 
including mmpl7 (associated with INH resistance) and p55 (associated with RIF resistance) 
[80]. However, it is unclear if EP inhibition is TZ’s primary mechanism of action, as they 
have a variety of targets in both bacterial and eukaryotic cells. Apart from its activity against 
EPs, TZ has other physiological targets involved in cellular respiration in M. tb. For instance, 
TZ blocks the electron transport chain in mycobacteria by inhibiting type II NADH 
dehydrogenases [81], succinate dehydrogenase and calcium binding to proteins [82]. TZ has 
also been implicated in M. tb cell envelope damage [83]. Apart from this wide variety of 
bacterial targets, phenothiazines like TZ also have a hypothesized effect in eukaryotic cells, 
enhancing the killing effect of macrophages [84]. The fact that TZ has several different 
mechanisms of action against TB reduces the risk of developing TZ resistance [85]. 
 
1.5.2 Combination therapy using antibiotics and efflux pump inhibitors 
To combat efflux-mediated tolerance in bacteria, a novel therapy involves a 
combination of EP inhibitors, such as TZ, with an antibiotic to which the organism has 
become resistant (Figure 1.1). Blocking active drug extrusion by bacterial EPs is expected to 
restore antibiotic susceptibility and therefore the curative potential of the drug [84, 86]. In the 
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first studies on CPZ, Crowle et al. already found a synergistic treatment effect of this drug 
with PZA, RIF and INH against bacteria inside macrophages [72]. This in vitro synergy was 
also seen when using TZ with SM and RIF against MDR-strains by Viveiros et al. [87]. 
Figure 1.1: Treating with traditional anti-TB drugs such as RIF will not clear intracellular infections with 
phenotypically resistant bacteria, which among other strategies can reduce RIF efficiency by up-regulating EPs. 
A novel therapy involves combining RIF with the EP inhibitor (EPI) TZ to clear both susceptible and 
phenotypically resistant bacteria. Modified from Szumowski et al. [88]. 
 
As mentioned above, most of the studies done on the antimicrobial effects of TZ and 
other phenothiazines have been done in vitro [74, 75]. However, there have been some in 
vivo studies in the TB mouse model, where bacillary load is quantified from the lungs. These 
studies show significant reductions in CFUs using both TZ monotherapy and combination 
treatment with antibiotics, although residual bacteria remained [85, 89, 90]. In one study, 
Dutta et al. [89] did not see any additional treatment effect when using TZ at 10 mg/kg alone 
or in combination with RIF, although it did improve INH treatment. On the other hand, van 
Soolingen et al. [85] showed that a higher dose of TZ was effective against both drug 
susceptible and resistant strains in vivo, both on its own and in combination with antibiotics. 
Daily administration of 32 and 70 mg/kg TZ in mice for two months both gave a five-fold 
decrease in CFUs of susceptible M. tb strains. However, due to toxicity concerns with the 
high dose of TZ, the lower dose of 32 mg/kg was preferred. Additionally, adding 32mg/kg 
TZ to the standard regimen using RIF, INH and PZA further reduced the bacterial burden in 
mice [85]. The EP inhibitor verapamil has also been used in vivo, where it potentiated the 
antimicrobial effect of standard TB antibiotics and reduced the rate of relapse [91]. 
Unlike most of the drugs in the anti-TB regimen, TZ also efficiently kills both 
actively growing M. tb and M. tb with hypoxia-induced dormancy [82]. This is a great 
advantage when it comes to dealing with the non-replicating persisters implicated in M. tb 
relapse and latent infections [85]. TZ’s potential against persisters together with its ability to 
increase the efficiency of the other drugs in our current antimicrobial arsenal makes it an 
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ideal drug to include in the anti-TB regimen. TZ has actually already been used for 
compassionate therapy in combination with second-line drugs in a few XDR-TB patients in 
Argentina and India, with promising results [92, 93]. However, the fact remains that TZ is 
associated with severe negative side effects, and these studies were therefore carried out 
under strict monitoring for cardiotoxicity. In this respect, limiting this toxicity is an important 
and necessary step before TZ can be considered for the standard anti-TB regimen. 
 
1.6 The Zebrafish model of mycobacterial infection 
1.6.1 The Zebrafish model of tuberculosis  
Several animal models are used to study TB, including rodents, rabbits and non-
human primates infected with M. tb itself and fish or frogs infected with Mycobacterium 
marinum (M. m) [94]. Among these models, TB in non-human primates most closely 
resembles the disease in humans [95]. Unfortunately, this model presents several ethical and 
practical difficulties, in addition to being prohibitively expensive for many studies. In 
contrast, mouse models using M. tb are less problematic and well established [94], but they 
do not accurately reflect many important aspects of the disease in humans. Importantly, 
granulomas in mice are not well organized and do not exhibit caseation, necrosis, fibrosis or 
calcification, which are characteristic traits of a TB granuloma in human patients [96, 97]. 
The zebrafish (Danio rerio), on the other hand, provides a simple yet powerful model 
for TB research due to its optical transparency and similarities to pathogenesis in human TB. 
The zebrafish is a small freshwater fish naturally found in India, Pakistan and Bhutan, which 
has become a common model organism used to study both developmental biology and human 
disease [98, 99]. Unlike the mouse model of TB, M. m infection in the zebrafish model yields 
caseating, well-organized granulomas, morphologically similar to granulomas in human TB 
[100, 101].  
Both zebrafish embryos and adult fish are susceptible to mycobacterial infection [102, 
103]. However, zebrafish embryos initially only rely on their innate immunity, with 
functional macrophages at 1 day post fertilization (dpf) [104]. Lymphocytes start appearing at 
4 dpf, but a mature adaptive immunity is only present after about 4 weeks [105]. Despite this 
lack of adaptive immunity, early embryonic macrophages can phagocytose the mycobacteria 
and form tight aggregates. These are histologically similar to granulomas found in adult 
zebrafish and humans and are accompanied by the up-regulation of granuloma-associated 
genes [103], although they have fewer lymphocytes [100]. This implies that the innate 
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immunity is sufficient to launch the granulomatous response, despite the fact that 
lymphocytes aid in controlling bacterial growth later in infection [100]. In this way, zebrafish 
have provided new insights into TB pathogenesis, as it was previously believed that adaptive 
immunity was required for granuloma formation [106]. 
The TB-like infection produced by M. m, often referred to as fish TB, can be treated 
using the same drugs as in human TB, which all efficiently clear M. m infections in zebrafish 
(except pyrazinamide, to which M. m is inherently resistant). Using combinations of the 
different drugs also significantly improves treatment, closely replicating human data [53]. 
Importantly, embryos are optically transparent for the first two weeks post fertilization, 
allowing for real-time imaging of infections and therapy [103]. In addition to this, zebrafish 
are relatively easy to maintain and breed, with a single female potentially laying up to 200 
eggs per week [99]. Zebrafish embryos develop quickly, with most of their important organs 
in place when they naturally hatch after three days [99]. Furthermore, the genomes of both 
zebrafish and M. m have been fully sequenced [107, 108], and a wealth of transgenic animals 
exist [100]. The relative ease of keeping zebrafish at high densities and their efficient 
production of embryos offers potential for high throughput analysis [109]. 
 
1.6.2 Mycobacterium marinum as a model for Mycobacterium tuberculosis 
M. m is a naturally occurring pathogen in fish and other ectotherms that causes a 
systemic granulomatous disease [101, 110]. M. m is one of the two closest relatives to M. tb 
outside the M. tb complex, the other being M. ulcerans [111], making it an obvious model for 
human TB in the zebrafish model. Unlike M. tb, which grows optimally at 37°C, M. m grows 
at 30-32 °C and therefore rarely causes systemic infections in humans but can rather cause 
superficial lesions known as “swimmer’s granulomas” [97]. M. m grows optimally in the dark 
[112] and has a generation time of four hours during logarithmic growth, compared to the 
>20 hour generation time needed for M. tb. As M. m grows relatively fast and is a biosafety 
level-2 (BSL-2) pathogen, it is easier to maintain and work with in the lab compared to the 
slow growing M. tb, which requires BSL-3 facilities [102]. Like M. tb, M. m infects 
macrophages and replicates intracellularly by arresting phagosome maturation to prevent 
phago-lysosome fusion, a mechanism that is essential to mycobacterial virulence [97, 101]. 
M. m has orthologs for 80% of all coding sequences in M. tb, and these have an average of 
85% amino acid identity [108]. The similarity to M. tb combined with the relatively short 
generation time and lower BSL requirements make M. m an ideal model for TB in the lab.  
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1.7 The nanoparticle approach to drug delivery 
1.7.1 Drug delivery using polymeric nanoparticles  
Conventional drugs administered in their free form face many complications when 
navigating a complex in vivo environment. They need to reach granulomas, which are 
heterogeneous and difficult to penetrate, making it hard to predict if the drug will be able to 
accumulate there. An additional level of complexity involves the fact that bacteria can exist 
both within macrophages in granulomas or in individual cells, or extracellularly in hypoxic 
caseating granuloma lesions or in liquefied cavities. Some of these bacteria may be dormant 
and some actively replicating [96]. Granulomas themselves also evolve over the course of an 
infection, starting out as mainly cellular structures that are easier to penetrate but 
progressively become less accessible to free drugs due to fibrosis and calcification [33]. 
Granulomas also differ in their extent of vascularization, which may not only limit the entry 
of oxygen and nutrients, but can also restrict transport of free drugs to the site of infection 
[49]. The difficulties of penetrating this complex and dynamic in vivo landscape are 
illustrated by the fact that levels of drugs actually accumulating in a granulomatous lesion are 
much lower than what is detected in the plasma. The consequence of this is that drugs that 
have high antimicrobial activity in vitro need to be administered for long periods of time, 
which can lead to non-compliance in patients [33]. This pharmacodynamic information was 
limited when the standard anti-TB regimen was designed and it is therefore thought that with 
current dosing standards sub-optimal amounts of RIF actually reach the granuloma. Due to 
this low efficiency, higher doses of RIF have been suggested for the standard treatment 
against TB [113]. 
Polymeric nanoparticles (NPs) are vehicles used for the delivery of drugs or other 
agents by means of their entrapment or adsorption to a polymer matrix or by chemical 
bonding to the polymer. Unlike free drug delivery, NP-based drug delivery allows more 
efficient targeting of drugs to the diseased site. It has been shown that NPs are rapidly 
phagocytosed by macrophages and brought to the granuloma for local release in zebrafish 
embryos [114]. The granuloma was previously regarded as a rigid structure but has now been 
observed to be more dynamic, with highly motile macrophages and the presence of both 
infected and non-infected macrophages at the necrotic core [27]. Instead of relying on chance 
penetration of a granuloma by diffusion through tissue or delivery by sporadic vasculature, 
NPs with RIF and other anti-TB drugs can efficiently be carried to the site of disease inside 
macrophages traveling to and from the granuloma, eliminating the need to increase drug 
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doses [114]. This high turnover of macrophages opens for the possibility that new NPs can 
continuously be brought to the granuloma with repeated administration of encapsulated 
drugs. However, this would rely on the assumption that the highly dynamic state lasts beyond 
the initial stages of granuloma formation, into the later stages of fibrosis and calcification, 
which may not be the case. 
Different authors vary somewhat in their ideas of the size range accepted under the 
definition of NPs, some of which set a range of 10-999 nm, which is the definition used here. 
The concept of using biodegradable polymers for the sustained release of drugs was first 
conceived in the 1970s [115]. Since then, nano- and micro-particle formulation using both 
natural and synthetic polymers have gained significant interest [116]. Unlike conventional 
free drug delivery, polymeric NPs can be tuned to slowly release drugs in a controlled 
manner, which contributes to keeping drug concentrations at therapeutically significant levels 
for longer periods of time. In addition, encapsulation can protect the content- especially in the 
case of small molecules, DNA or peptides- from degradation and rapid clearance from the 
body [116]. 
NP-delivery facilitates local administration, as particles can in theory be targeted 
passively or actively to exactly where they are needed. Active targeting involves 
functionalizing the surface with affinity ligands such as antibodies. Passive targeting, on the 
other hand, does not require any additional ligands as NPs of submicron size are rapidly 
recognized and taken up by professional phagocytes [114]. Instead of administering high 
amounts of drug to raise the concentration in the plasma, NPs can be taken up by 
macrophages and other phagocytes, including neutrophils and monocytes. In this way, less 
drug can be administered as therapeutic concentrations are achieved locally, sparing healthy 
tissue from toxic side effects associated with free drug delivery [117]. 
 
1.7.2 Nanoparticles for tuberculosis therapy 
NP treatment against TB has gained interest due to research by Gopal Khuller and his 
group, working on murine and guinea pig models of TB. They were able to show that NP 
delivery improved drug efficiency and reduced the number of doses needed for an improved 
treatment effect [118-122]. Our group has also shown that NPs localize at the site of infection 
[114], and RIF encapsulated in NPs is more efficient in clearing mycobacterial infections 
relative to the corresponding dose of free RIF, both in vitro [123] and in the zebrafish model 
[114]. Using NPs for TB therapy may contribute to shorten the duration of treatment, reduce 
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frequency of dosing and improve delivery by passive targeting and local release. This new 
approach to our current anti-TB treatment would be a great advantage in reducing non-
compliance and improving treatment efficacy. Passively targeted NPs can be delivered by 
macrophages to the site of disease, and slow release inside the granuloma, which is normally 
difficult to penetrate, can help to keep the drugs at therapeutic concentrations and for an 
adequate amount of time [49, 114]. 
 
1.7.3 Encapsulation using the copolymer poly(lactic-co-glycolic) acid  
Poly(lactic-co-glycolic) acid (PLGA) is a copolymer commonly used for drug 
delivery, including the formulation of nano- and microspheres [124]. In the presence of 
water, the ester linkages in the PLGA polymer are broken down by hydrolysis to yield the 
monomers lactic acid and glycolic acid. These are byproducts of normal cellular metabolism, 
and can therefore be broken down to carbon dioxide in the citric acid cycle under 
physiological conditions [125]. Due to its biocompatible and biodegradable nature, PLGA is 
not considered toxic and has been FDA-approved for use in human therapy [124, 125]. 
PLGA copolymers can be synthesized with different ratios of lactic acid to glycolic 
acid, where a higher proportion of lactic acid makes the polymer more hydrophobic and less 
biodegradable. PLGA with equal ratios of both monomers (PLGA 50:50) has the fastest rate 
of degradation and is therefore the most biocompatible [126]. The rate of drug release from 
the NPs is determined by both polymer degradation and drug diffusion through pores or the 
remaining polymer matrix. This in turn depends on the nature and size of the drug molecule 
and polymer. In addition, a drug may be loosely attached to the particle surface or embedded 
in the particle surface [115]. In order for this drug to be internalized in cells, the NPs need to 
be taken up by macrophages phagocytosis. Both uptake and bio-distribution of NPs is, 
therefore, dependent on the physical properties of NPs, including size, surface charge, 
hydrophobicity and immunogenicity [116]. 
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2 Aim 
This master’s thesis aims to (1) develop a protocol for the encapsulation of TZ in polymeric 
PLGA NPs, (2) compare the toxicity of free TZ with that of encapsulated PLGA-TZ and (3) 
use PLGA-TZ NPs together with PLGA-RIF NPs to explore the ability of EP inhibitors to 
potentiate antibiotic therapy. These aims will be investigated using an in vitro model of 
murine macrophages infected with Mycobacterium bovis BCG and in vivo using the zebrafish 
model infected with M. m.  
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3 Materials and methods  
3.1 PLGA nanoparticle preparation 
3.1.1 Single emulsion 
This protocol was adapted from Kalluru et al. 2013 [123]. Making NPs by single 
emulsion (oil-in water emulsion), requires the preparation of two non-miscible phases, one of 
which is organic and the other aqueous [116]. Depending on the application of the resulting 
NPs, this method can be used for the encapsulation of hydrophobic dyes (such as coumarin-6) 
to facilitate imaging, or hydrophobic drugs (such as RIF or TZ) to use in treatment 
experiments. Regardless, the compound to be encapsulated is dissolved in an organic solvent 
together with the PLGA polymer to make the organic phase. The aqueous phase consists of 
polyvinyl alcohol (PVA), which acts like an emulsifier that stabilizes the particles and makes 
them water-soluble. The size of NPs depends on many factors, including polymer 
concentration, amount of emulsifier added, drug loading, miscibility of phases, the ratio of 
water to solvent and the amount of energy applied during NP preparation [127].  
 
The following compounds were encapsulated: 
• RIF (Sigma-Aldrich, St. Louis, MO, USA)  
• TZ base (Sigma-Aldrich, St. Louis, MO, USA), made by our collaborators in Bo 
Nystrøm’s group at the University of Oslo by removing the hydrochloride group from 
TZ-hydrochloride to yield hydrophobic, free base form, as described in US patent 
4722948 [128]. 
• Coumarin-6 dye with green fluorescence (Sigma-Aldrich, St. Louis, MO, USA),  
 
The following copolymers were used for encapsulation: 
• PLGA (50:50) Resomer® RG 502 (Evonik Röhm GmbH, Darmstadt, Germany) 
containing equal ratios of both monomers lactic acid and glycolic acid. 
• PLGA (75:25) Resomer® RG 752 S (Evonik Röhm GmbH, Darmstadt, Germany) 
containing 75% lactic acid and 25% glycolic acid. 
• PLA Resomer® RG 202 S (Evonik Röhm GmbH, Darmstadt, Germany) containing 
100% polylactic acid. 
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To prepare the organic phase, 100 mg of polymer, and 100 mg of the drug or dye to 
be encapsulated were dissolved in 10 ml dichloromethane (DCM; Sigma-Aldrich, St. Louis, 
MO, USA) in a small Erlenmeyer flask sealed tight with parafilm and left stirring over night 
to allow the solutes to completely dissolve. For the aqueous phase, 1% or 4% PVA (average 
molecular weight 57-66 kDa; Alfa Aesar, Ward Hill, MA, USA) was dissolved in 20 ml 
distilled water under heated stirring at 80°C in a sealed glass bottle for 1 hour. Once there 
were no visible PVA crystals, the heat was turned off and the solution was left stirring 
overnight to ensure complete dissolution. To form the emulsion, the aqueous phase was 
filtered using a 0.22 µm filter into a small beaker, before the organic phase was mixed in. The 
solution was consequently sonicated using a tip sonicator (Power 750 Watt, Sonics & 
Materials Inc., Church Hill Road, Newtown, USA) for 3 minutes at 450 Watt (60% of the 
maximum power output). To evaporate the unwanted organic solvent (DCM), the emulsion 
was divided into two small Erlenmeyer flasks and left stirring overnight. Importantly, the 
flasks were covered with aluminum foil with a 2 mm hole to facilitate slow, gradual 
evaporation of the DCM. This prevents disruption of the NP polymeric matrix, which can 
cause premature drug release.  
 
Figure 3.1: Schematic overview of PLGA NP preparation by single (oil-in water) emulsion 
 
Following DCM evaporation, the solidified NPs remain in aqueous suspension. This 
suspension was transferred to ultracentrifugation tubes and weighed to confirm the 
evaporation of the organic solvent. The particles were consequently washed twice by 
ultracentrifugation at 10,000 rpm (17,000 × g) using a SW32 Ti rotor (Beckman Coulter, 
Fullerton, CA, USA) for 15 minutes using sterilized milliQ water to remove excess PVA. The 
resulting pellet was then re-suspended in 2 ml 2.5% trehalose (Sigma-Aldrich, St. Louis, MO, 
USA), a cryo-protectant for the subsequent lyophilization. Lastly, this suspension was 
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transferred to a cylindrical glass flask and slowly rotated at an angle in a liquid nitrogen bath 
to allow it to freeze in a thin layer. The frozen flask was then attached to a freeze dryer 
(Freezone 2.5, Labconco, Kansas City, MO, USA) and left for 24 hours, enough to allow 
complete sublimation of the water in the suspension. The resulting dried NPs were then 
scraped out using a spatula and stored at 4°C. The procedure is summarized in Figure 3.1. 
 
3.1.2 Nano-precipitation 
Nano-precipitation is another method used to make polymeric NPs. Compared to 
single emulsion, this is a simpler and milder technique in that it does not require sonication. It 
can therefore be suitable for encapsulating more sensitive compounds such as DNA. 
However, single emulsion usually leads to a higher encapsulation efficiency and final drug 
loading than nano-precipitation [116]. Like single emulsion, this method combines an 
aqueous phase with an organic phase; however, with this technique a water-miscible solvent 
is used to dissolve the drug/dye and the PLGA polymer. Although this method can be used 
for the encapsulation of hydrophilic compounds, it is more suited for hydrophobic 
compounds due to the propensity of hydrophilic substances to escape the organic phase and 
stay in the water phase [116]. To make the aqueous phase, a 1% weight/volume (w/v) PVA 
solution was prepared as described in section 3.1.1. To make the organic phase, 20 mg of 
PLGA (50:50) and 20 mg of drug, in this case TZ, were dissolved in 1 ml dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, St. Louis, MO, USA). Both solutions were left stirring overnight to 
allow complete dissolution. The following day, 5 ml of the 1% PVA was filtered using a 0.22 
µm filter into a beaker. Under magnetic stirring, the organic phase was added drop-wise to 
the aqueous phase using a 22 gauge needle and 1 ml syringe at a rate of approximately 0.5 
ml/min. The solution was left stirring for 5 hours before the NPs were washed by 
centrifugation and freeze dried as described in section 3.1.1. 
 
3.2 Nanoparticle characterization 
3.2.1 Measurement of nanoparticle drug loading 
The amount of drug encapsulated in PLGA-RIF and PLGA-TZ NPs was quantified by 
means of High Pressure Liquid Chromatography with UV detection (HPLC-UV) in Steven 
Wilson’s analytical chemistry lab at the University of Oslo [123]. Standard curves were made 
using free drug. For both particle types, 1 mg/ml solutions were made in acetonitrile (ACN; 
HiPerSolv Chromanorm, VWR, Radnor, PE, US) and sonicated for 15 minutes to dissolve 
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the NP and release the encapsulated drug. The samples were centrifuged to pellet the NP 
debris (13,000 × g, 1 minute), and the supernatant containing free drugs was analyzed by 
HPLC. When necessary, the samples were diluted 10 times before injection. The samples 
were injected by an Agilent 1200 series GL1377A micro WPS auto sampler (Agilent 
technologies, Palo Alto, CA, USA). RIF was separated with an ACE3 C18 column, and TZ 
was separated with an ACE3 C8 column (both with 4.6 mm x 150 mm inner diameter; 
Advanced Chromatography Technologies, Aberdeen, UK). An Agilent 1100 series GL1378 
pump was used to deliver a mobile phase at a flow rate of 1 µl/min. In the case of RIF, the 
mobile phase consisted of 70% ACN and 0.1% formic acid in water. In the case of TZ, the 
mobile phase consisted of 50% ACN and 0.1% formic acid in 10mM ammonium formate (pH 
6.3). The analytes were detected using an Agilent 1200 series GL1365D MWD detector set to 
480 nm for RIF and 254 nm for TZ. Each measurement was based on three independent 
samples.  
 
3.2.2 Transmission electron microscopy 
To visualize and estimate the size range of the manufactured NPs we used 
transmission electron microscopy (EM). Dry NPs were re-suspended in milliQ water at 0.5 
mg/ml. A drop of this suspension was placed on a sheet of parafilm. Using forceps, a clean 
hexagonal formvar grid was floated on the drop for 1 minute to allow the NPs to attach. 
Subsequently, the grid was floated on four drops of water, one after another, to remove any 
unattached NPs. Then the sample was treated with negative stain by floating the grid on a 
drop of 3% uranyl acetate solution for 30 seconds. This is done to achieve the contrast 
necessary for visualization against the grid background [129]. Excess uranyl acetate was 
removed by gently touching a filter paper. The grid was allowed to air dry at room 
temperature (RT) before loading it on the EM sample holder. The imaging was performed 
with a Phillips transmission EM (CM100; Philips, Eindhoven, The Netherlands). Using a 
focused electron beam, the sample was visualized as it interacts with and scatters electrons. 
The images were recorded digitally with a Quemsa TEM CCD camera and iTEM software 
(Olympus Soft Imaging Solutions, Germany). 
 
3.2.3 Measurement of nanoparticle surface charge and size 
The Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK) is 
an instrument used to measure NP hydrodynamic diameter by dynamic light scattering at one 
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angle (backscatter at 173°) [130]. In addition to diameter, the variation in size of the particles 
was quantified in terms of the polydispersity index (PDI). Surface charge was also 
determined by means of the electrophoretic mobility, or movement of NPs in an applied 
electric field, which is expressed as the zeta-potential. These measurements revealed 
important physical characteristics of the NPs that can affect their uptake and circulation time. 
PLGA-RIF and PLGA-TZ were re-suspended at 1 mg/ml in distilled water prior to 
measurement of diameter, PDI and zeta-potential at 25°C. The samples were added to 12-mm 
glass cell PCS1115 capped cuvettes fitted with dip-cell palladium electrodes with 2 mm 
spacing, and placed inside the Zetasizer for measurement.  
 
3.3 In vitro infection and treatment 
3.3.1 Isolation and differentiation of primary murine macrophages 
Primary bone marrow derived macrophage cells were isolated from mouse bones 
using an adapted protocol from Kalluru et al. [123]. Four to twelve week old C57BL/6 mice 
(male and female) were sacrificed by cervical dislocation and soaked in 70% ethanol. Using 
sterile equipment, the femur and tibia were dissected out and soaked in PBS (Sigma-Aldrich, 
St. Louis, MO, USA) for 5 minutes to soften any remaining tissue. Using autoclaved tissues, 
the bones were thoroughly rubbed to remove the softened tissue. The clean bones were 
consequently placed in 70% ethanol and quickly transported to a sterile hood. Once in the 
hood, the bones were immediately washed three times with PBS to remove any residual 
ethanol. Clean bones were kept in PBS to prevent them from drying out. Using sterile 
scissors, the ends of the bones were carefully cut off to reveal the bone marrow inside. The 
marrow was harvested from both ends by injecting RPMI 1640 cell culture media (Lonza, 
Basel, Switzerland) through the central cavity in the bones using a 5 ml syringe fitted with a 
25 gauge needle. The marrow was collected in a non-treated culture dish and re-suspended in 
cell media. This suspension was then collected in a 50 ml falcon tube and centrifuged at 400 
×g for 5 minutes, yielding a red pellet containing both red blood cells and mononuclear cells. 
To selectively remove the red blood cells, the pellet was re-suspended in red blood cell lysis 
buffer (Sigma-Aldrich, St. Louis, MO, USA) and incubated until the media turned yellow, 
indicating that the lysis is complete approximately after 3-5 minutes. To stop the lysis, fresh 
cell media was added and the cells were again spun down at 400×g for 5 minutes. One can 
verify that the lysis has been successful because the removal of red blood cells makes the 
pellet appear yellow. The supernatant was again discarded and replaced with full RPMI 
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primary macrophage media, supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich, 
St. Louis, MO, USA), 1% Penicillin-Streptomycin (PS; corresponds to 50 U/ml of each 
antibiotic; Sigma-Aldrich, St. Louis, MO, USA) and 50 µM β-mercaptoethanol (Sigma-
Aldrich, St. Louis, MO, USA). To differentiate the monocytes into macrophages, 40 ng/ml 
recombinant murine macrophage colony-stimulating factor (M-CSF; ImmunoTools, 
Friesoythe, Germany) was added to the cell media. Alternatively, 20% L929 conditioned 
media was used as a source of M-CSF. Conditioned media was made by collecting media 
used for culturing L929 murine fibroblasts, which secrete M-CSF. Finally the cell suspension 
was filtered into a new 50 ml falcon tube using a 70 µm cell strainer (BD Biosciences, 
Franklin Lakes, NJ, USA) in order to remove any residual bone and tissue. The cells were 
plated in non-treated culture dishes at a density of approximately 8×106 cells per dish and 
allowed to differentiate for 6-7 days, changing the media every other day. Allowing the 
isolated cells to differentiate on non-treated culture dishes selects for mononuclear cells, as 
these have a relatively higher binding affinity than other cell types present in the bone 
marrow [131]. After differentiation, the cells can be scraped and either be used immediately 
or frozen at - 80°C in FCS with 10% DMSO for future use. 
 
3.3.2 Macrophage characterization by CD14 immunolabeling  
Macrophages were characterized by preforming CD14 immunolabeling. CD14 is 
considered a specific marker for monocytes, normally expressed late in monocyte 
differentiation [132] Treated cells were imaged using a upright confocal laser scanning 
microscope, (FluoView 1000 BX61W1, Olympus, Tokyo, Japan). For the CD14 
immunolabeling, frozen primary macrophages were thawed and plated at a density of 
4.8×105 cells per well on 14 mm glass coverslips coated with poly-L-lysine (see appendix, 
supplementary methods). To maintain the differentiated state, 20% L929-conditioned media 
was used. RAW macrophage cells were also seeded as a positive control. After allowing one 
day for recovery, cells were washed with PBS and then fixed for 15 min using 4% 
paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) in PBS. Cells were then incubated 
for 1 hour at RT in 1% (w/v) BSA in PBS with 0.1% tween prior to addition of primary 
antibody solutions (Rat anti-mouse CD14; BD biosciences, Franklin Lakes, NJ, USA) at two 
concentrations, 1:100 and 1:500 in all wells except negative controls. Cells were left in 
primary antibody solutions overnight at 4°C. The following morning a PBS wash was done 
before adding a secondary antibody, conjugated to a red fluorescent marker (cy3 anti-rat; 
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Jackson ImmunoResearch, West Grove, PA, USA) at a concentration of 1:500 for 1 hour at 
RT. Lastly, cells were washed again and nuclei were stained with Hoechst (Sigma-Aldrich, 
St. Louis, MO, USA) 1:1000 in PBS. The coverslips were given a final wash before they 
were mounted on microscope slides and fixed in place using mowiol (Sigma-Aldrich, St. 
Louis, MO, USA) as an adhesive. These slides were imaged in the confocal microscope. 
 
3.3.3 RAW cell culture 
RAW macrophages were kept in DMEM cell media (Sigma-Aldrich, St. Louis, MO, 
USA) supplemented with 1% PS and 10% FCS. Cells were passaged 1:4 every second day 
and seeded on treated culture dishes or poly-L-lysine treated glass coverslips for confocal 
imaging. Cells were used for a maximum of 20 passages. 
 
3.3.4 Macrophage uptake of fluorescent nanoparticles 
To confirm macrophage phagocytosis, freshly isolated primary murine macrophages 
were treated with NPs loaded with the dye Coumarin-6, which exhibits green fluorescence. 
Cells were seeded at a density of 3.8×105 cells/well on poly-L-lysine coated glass coverslips. 
NPs were re-suspended in full primary macrophage media and sonicated for 3 minutes. The 
NP solution at a concentration of either 25 µg/ml or 50 µg/ml was then added to the cells and 
left to incubate at 37°C to allow macrophage uptake. After 3 hours, cells were washed three 
times with PBS and fixed with 4% paraformaldehyde for 10 minutes. The fixed cells were 
washed again in PBS and mounted on microscope slides using mowiol as an adhesive. These 
slides were imaged in the confocal microscope. 
 
3.3.5 CCK-8 viability assay 
The Cell Counting Kit 8 (CCK-8; Sigma-Aldrich, St. Louis, MO, USA) was used to 
determine the toxicity of free and encapsulated TZ in primary macrophage culture. This assay 
was also used to test the effect of M-CSF on cell viability. CCK-8 is a colorimetric assay that 
uses the tetrazolium based salt WST-8, which is reduced by dehydrogenases in the cell, 
producing a brown color that is proportional to the amount of viable cells in the sample [133]. 
Primary murine macrophages were seeded at a density of 4×104 cells per well in 
transparent 96-well cell culture plates. To maintain the macrophages in a differentiated state, 
40 ng/ml M-CSF was added fresh at each media change. After seeding, the cells were left 
overnight to allow them to settle in a monolayer. The next day they were treated with either 
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free TZ or the corresponding concentrations of TZ encapsulated in PLGA NPs. While the NP 
suspension was only left on the cells for three hours, the free drug was added continuously 
throughout the experiment. After three hours, all the cells (free drug and NP treated) were 
washed with 37°C PBS, and replaced with fresh media supplemented with free TZ where 
appropriate. To prepare the treatment conditions, the TZ (free and encapsulated) used for 
treatment was first dissolved in RPMI cell media (with 1% PS and 10 % FCS) at a 
concentration of 1 mg/ml. These stock solutions were then diluted in full RPMI (with 1 % 
PS, 10% FCS and 40 ng/ml M-CSF) to achieve a final concentration corresponding to 2.5 
µg/ml, 5 µg/ml or 7.5 µg/ml of free TZ. Cells were also treated with empty PLGA NPs and a 
combination treatment with particles equivalent to 5 µg/ml TZ and 8 µg/ml RIF. 
Measurements using the CCK-8 reagent were done at 3, 6 and 9 days, with three 
replicates per condition. The media was removed and the cells were washed once using 37°C 
PBS. Clear RPMI (without phenol red) was mixed with 5% (v/v) CCK-8 reagent and added 
to each well, prior to a 40 minute incubation at 37°C. The reagent was also added to wells 
with no cells to measure background absorbance. After the incubation, 100 µl of the reagent 
was sampled from each well and placed in a new transparent 96 well plate. This was then 
brought to a plate reader (Victor2, PerkinElmer, Waltham, MA, USA), and absorbance was 
read at 450 nm for 0.1 seconds. 
 
3.3.6 Culturing BCG 
BCG transformed with a plasmid coding for the red fluorescent dsRed protein and 
hygromycin resistance (BCG dsRed, gift from Nathalie Winter and Brigitte Gicquel from the 
Pasteur Institute, Paris) were kept in liquid culture at 37°C. Liquid culture medium was 
prepared using Difco Middlebrook 7H9 broth supplemented with 0.02% glycerol (Merck 
KGaA, Darmstadt, Germany), 10% OADC (oleic acid (Sigma-Aldrich, St. Louis, MO, USA), 
albumin (Sigma-Aldrich, St. Louis, MO, USA) dextrose/glucose (Merck KGaA, Darmstadt, 
Germany) and 0.025% Tween 80 (Sigma-Aldrich, St. Louis, MO, USA). Hygromycin 
(Sigma-Aldrich, St. Louis, MO, USA) was added at 50 µg/ml to select for fluorescent BCG. 
To start new liquid culture, either a single colony grown on solid media was picked, 
or frozen stock was added to full 7H9 media. Bacteria were grown on solid media at 37°C on 
Difco Middlebrook 7H10 agar plates (see appendix, supplementary recipes) with OADC and 
50 µg/ml hygromycin. Plates were sealed in plastic bags to prevent them from drying out. 
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3.3.7 Primary macrophage infection and time-kill assay 
Freshly isolated primary murine macrophages were seeded in cell-culture treated 12 
well plates at a density of 5×105 cells per well and left to settle overnight. The next day, 
infection media was prepared by harvesting log phase (OD600 0.4-0.9) dsRed-BCG at 3000×g 
for 10 minutes. The BCG were washed twice using PBS, re-suspended in RPMI cell media 
and sonicated for 10 minutes in a bath sonicator to ensure a homogenous suspension. The 
BCG suspension was diluted to an OD of 0.035 (3.5 5x106 CFU/ml) in RPMI cell media, and 
added to the plated cells for infection for 3 hours. To calculate multiplicity of infection 
(MOI), the number of bacteria are divided by the number of macrophages in the well. In this 
case, the MOI was 7. After infection, cells were washed twice with warm PBS in order to 
remove any extracellular bacteria. Fresh full RPMI was added to all wells for 1 hour to allow 
the cells to recover from infection. During this time, treatment solutions containing PLGA-
RIF, PLGA-TZ or free RIF and free TZ were prepared for all conditions, using the 
concentrations summarized in Table 3.1. The seven combinations tested are listed in Table 
3.2. Each condition was prepared in triplicate for each time-point, and treatments were added 
to the cells for 3 hours. 
 
Table 3.1: Concentrations of RIF and TZ used for the CFU time-kill assay expressed as free drug weight and 
corresponding weight of PLGA NPs. 
 
 NP loading Free drug Encapsulated drug 
PLGA-RIF NP  31.8% 8.0 µg/ml 25 µg/ml 
PLGA-TZ NP low 26.5% 2.5 µg/ml  9.4 µg/ml 
PLGA-TZ NP high 26.5% 5.0 µg/ml 18.8 µg/ml 
 
 
Table 3.2: Summary of treatment conditions used for the time-kill assay. 
 
Condition 
RIF added TZ added 
8.0 µg/ml 2.5 µg/ml 5.0 µg/ml 
1 BCG control - - - 
2 PLGA-RIF NP + - - 
3 PLGA-TZ NP low - + - 
4 PLGA-TZ NP high - - + 
5 Combination NP low  + + - 
6 Combination NP high + - + 
7 Combination free  + - + 
Concentrations represent actual drug weight, not NP weight 
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In order to compare sustained release of the NPs with free drugs, a combination 
treatment using 5.0 µg/ml of TZ and 8.0 µg/ml RIF was included. Treatment with free drug 
had the same duration as the NP treatments. Following treatment, cells were again washed 
twice with warm PBS. Fresh full RPMI cell media supplemented with cytokine was then 
added to all wells. Cell lysis was carried out after 3 hours, 3 days, 6 days and 9 days of 
treatment. To do this, cell media was aspirated and 1 ml of RT 0.005% SDS (Sigma-Aldrich, 
St. Louis, MO, USA) in sterile milliQ water was added to each well. After 5 minutes, the 
contents of each well was pipetted up and down five times in order to aid cell lysis. The 
lysate was subsequently collected in an eppendorf tube. A dilution series was made for each 
sample in warm PBS, and these were plated on pre-warmed 7H10 agar plates supplemented 
with OADC and 50µg/ml hygromycin. Plates were incubated at 37°C in sealed plastic bags 
for 16 days, just enough to allow visible colonies to form for CFU enumeration. 
 
3.4 BCG luciferase assay 
3.4.1  Isolation of Luciferase plasmid 
Luciferase is an enzyme found in fireflies with a half-life of three hours in cells. Upon 
the addition of adenosine triphosphate (ATP), magnesium and the luciferase substrate, 
luciferin, the enzyme will produce a bioluminescent signal, as shown in Figure 3.2. The luc 
gene, which produces the luciferase enzyme can be introduced to bacterial cells by 
transformation and serve as a reporter for the amount of viable bacteria in a sample  
Figure 3.2: Schematic showing the luciferase reaction that forms the basis of the luciferase assay. The luc gene 
coding for the luciferase enzyme can be transformed into bacteria. The bacteria can then be lysed, releasing the 
enzyme that, when exposed to its substrate D-luciferin, produces a bioluminescent signal and necessary 
cofactors ATP, oxygen and magnesium. 
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E. coli DH5α transfected with the plasmid pMH109-luc coding for firefly luciferase 
(and hygromycin resistance) was kindly sent to us by Trude Flo (NTNU, Trondheim, 
Norway), who in turn received it from David Sherman (University of Washington, Seattle, 
WA, USA) [134]. In addition to hygromycin resistance, the plasmid encodes features of the 
mycobacteriophage L5, including an attP site that efficiently targets the plasmid to the attB 
site in mycobacterial chromosomes, and an integrase that promotes this incorporation process 
[135]. Inside mycobacteria, pMH109-luc is constitutively expressed under a mycobacterial 
optimal promoter (MOP) on the plasmid. 
 The DH5α cells were cultured overnight in LB Media with 150µg/ml hygromycin. 
The next day the overnight culture was streaked out on LB-agar plates with 150µg/ml 
hygromycin. These colonies were used to make new liquid culture utilized for plasmid 
isolation and glycerol stocks. The plasmid was isolated using a maxi prep kit from 
Nucleobond (Macherey-Nagel GmbH & Co. KG, Düren, Germany). Plasmid purity was 
checked using NanoDrop™ (Thermo Scientific, Wilmington, DE, USA), which revealed that 
the 260/280 value was 1.88. 
 
3.4.2 Electroporation of wild type BCG with luciferase plasmid 
The following was adapted from Goude et al. 2008 [136]. Wild type BCG were given 
to us by Tone Tønjum (Rikshospitalet, Oslo, Norway). These were grown until exponential 
phase, in this case an OD600 of approximately 0.5. Cultures were kept on ice for 1 hour, and 
then harvested by centrifugation at 3000×g for 10 minutes. This was followed by three 
washes using ice-cold 10% (v/v) glycerol in milliQ water. The volume of 10% glycerol used 
was reduced with each wash from 30ml to 5 ml and lastly 1 ml. The isolated plasmid and 
BCG were kept on ice. Three eppendorf tubes were prepared with 200µl ice-cold BCG 
culture. DNA was added to two of the tubes at 1 µg and 2µg. The last tube remained as a 
negative control with no DNA added. The samples were incubated for 10 minutes on ice, and 
then transferred to 2 mm re-usable electroporation cuvettes (BTX, Harvard Apparatus, 
Holliston, MA, USA). This was done carefully, avoiding bubbles in order to minimize the 
chance of arcing, an electric discharge that can kill the bacteria in the sample. 
The cuvettes were placed in the slot of an electroporator (Bio-Rad, Hercules, CA, 
USA) set to -2.5 kV, 25 µF and 600 Ohm. Immediately after electroporation, 1 ml warm 7H9 
was added to the cuvette, and the contents were transferred to a new eppendorf tube. The 
transformed bacteria were allowed to recover at 37°C for 4 hours. To select for transformed 
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individuals the bacteria were plated out on 7H10 plates with OADC supplement and 50µg/ml 
hygromycin. Once colonies had grown, after approximately 3 weeks, BCG transformed with 
luciferase (BCG-lux) were cultured in the same way as dsRed BCG.  
 
3.4.3 Correlation of CFU with luciferase quantification 
Frozen primary murine macrophages were plated out in non-treated cell culture dishes 
and left to recover for 3 days at 37 °C. Cells were then scraped and seeded at a density of 
500,000 cells/well on two 12-well plates and allowed to settle in a monolayer. The following 
morning, BCG lux cultures were processed for macrophage infection as described in section 
3.3.7. Infection media was added to cells in duplicates at the following OD600: 0.05, 0.01, 
0.005, 0.001 and 0.0005. This range corresponds to 5x106-5x104 bacteria, or an MOI of 10-
0.1. Duplicate wells were mock infected for luciferase controls. The day after infection, 
macrophages were lysed by incubating them for 5 minutes in 0.005% SDS in milliQ water as 
before. This causes the release of intracellular bacteria which can either be plated out or lysed 
and processed for luciferase quantification.  
Samples to be quantified by CFU were subjected to serial dilutions and plated out on 
warm 7H10 plates with OADC and 50 µg/ml hygromycin. Plates were sealed in plastic bags 
and left at 37°C. Colonies were counted after 3 weeks.  
Samples to be quantified by luciferase assay were spun down at 5000 rpm (2400×g) 
for 3 minutes to collect the bacteria, and the supernatant was removed. Samples were spun 
down a second time to ensure all residual supernatant was removed, and finally re-suspended 
in 20µl 1x passive lysis buffer (from the dual luciferase assay kit; Promega, Madison, WI, 
USA), thoroughly vortexed and briefly sonicated to mix. Samples were then left on ice for 10 
minutes, followed by a second vortex and sonication to ensure complete lysis of the bacteria. 
This caused the release of the luciferase enzyme produced by viable bacteria. The 
reconstituted luciferase substrate is kept at -80°C as instructed by the manufacturer. This 
substrate contains ATP, luciferin, and magnesium required for the bioluminescent reaction. 
The substrate was prepared by thawing it in a 24 °C water bath for 30 minutes to ensure that 
the solution was at RT. If the substrate is too cold, it can reduce the signal produced by the 
reaction. For luciferase quantification, the 20µl bacterial samples were added four at a time to 
a white, opaque 96-well plate (Corning Inc., Corning, NY, USA). With strict attention to 
timing, 100µl of the luciferase substrate was added to each of these wells, with 2 seconds 
between each addition. After 25 seconds had passed from the addition of substrate to the first 
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well of the series, the plate was placed inside a Victor2 plate reader (PerkinElmer, Waltham, 
MA, USA) set to luciferase detection for 1 second per sample and a delay of 2 seconds 
between each reading. For graphical representation, the values were normalized to the highest 
value obtained and expressed as relative light units (RLUs). 
 
3.5 In vivo infection and treatment 
3.5.1 Zebrafish care and husbandry 
Zebrafish were kept in our facility at the University of Oslo. Aquaria were kept at 
28°C, with continuous circulation of tank water containing Instant Ocean ® sea salt (United 
Pet Group, Blacksburg, VA, USA), calcium chloride, and sodium bicarbonate. 
Approximately 10% of the total system volume was exchanged daily, and the light cycle was 
kept at 12:12 hours. Fish were fed three times daily, twice with brine shrimp and once with 
dry feed. For maximum output, fish were allowed to rest for two weeks between each 
breeding. The night before fish were bred, a small plastic box filled with two layers of glass 
marbles was placed in a tank with a male/female ratio of 3:2. The fish start breeding at dawn, 
or just after the light comes on in the morning and lay their eggs between the marbles where 
the other fish in the tank cannot reach and eat them. After allowing 3 hours of breeding, the 
box with marbles was carefully removed from the tank and the eggs harvested using a sieve. 
Fertilized eggs were washed carefully several times using embryo water (see appendix, 
supplementary recipes), and any abnormal-looking eggs (unfertilized or dead) were removed. 
Clean eggs were kept in fresh embryo water in petri dishes with no more than 100 eggs per 
dish in an incubator set to 28°C. After about 30 hours (1 dpf), eggs were manually 
dechorionated using forceps. Embryo water was changed daily prior to and for the duration of 
all experiments. Dechorionated embryos were ready for injections at 2 dpf. The strains used 
for survival and toxicity studies were “Casper” (roy-/-; nacre-/-; a gift from Darren Gilmour, 
EMBL, Heidelberg, Germany) which maintain optical transparency throughout embryo and 
adult life [137]. This lack of pigment makes it easier to preform experiments and is useful for 
imaging at later time- points. 
In the experiments that exceeded 6 dpf and zebrafish initiated feeding, we fed the 
larvae with rotifers. Ethical permission was obtained for animal experimentation from the 
Norwegian national animal research authority (FOTS permission ID 5214). 
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3.5.2 Toxic indicators in zebrafish  
 Equal concentrations of free or encapsulated TZ in 2% (w/v) polyvinyl pyrrolidone in 
PBS (2% PVP, molecular weight 10 kDa; Merck KGaA, Darmstadt, Germany) were injected 
in zebrafish embryos at 3 dpf. Mock injections consisted of 2% PVP only. Embryo water was 
changed daily, and feeding with rotifers (see appendix, supplementary methods) was initiated 
at 6 dpf. Embryos were monitored daily to record mortality, swim bladder inflation (see 
Figure 3.3), yolk discoloration and pericardial edemas [138-140]. To quantify this, a disease 
score was calculated based on the toxic indicators. Each indicator was given a score of either 
0,1 or 2, where 0 is the absence of the trait and 1 or 2 indicates two levels of severity, as 
summarized in Table 3.3. Examples of the different degrees of edema severity are shown in 
Figure 3.4. 
 
Table 3.3: Scores assigned to morphological toxic indicators in order to quantify the effect of injecting free and 
encapsulated TZ at 32 mg/kg. Adding the scores outlined in this table together gave the value reported as 
disease score. 
 
Trait 
Score 
0 1 2 
Edema No edema Small edema Severe edema 
Swim bladder inflation Yes No - 
Yolk sac discoloration (necrotic spots) Yes No - 
Heart-rate Normal Abnormal - 
 
 For heart rate quantification, un-sedated embryos were transferred to a 2% agar 
injection plate in a drop of water. Using a Leica M205 FA stereomicroscope (Leica 
microsystems, Wetzlar, Germany), the heart was brought into focus, and a 10-second video 
was recorded for each fish. The image sequence was imported into the image processing 
software Fiji [141] and heartbeat was quantified using a counter. These values were 
multiplied by 6 to obtain beats per minute (bpm). 
 
 
 
 
 
 
Figure 3.3: A representative “Casper” embryo with inflated swim bladder (highlighted by arrow) at 7dpf in 
lateral (top) and dorsal (bottom) projections. 
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Figure 3.4: Zebrafish larvae at 1dpt or 2dpt, displaying pericardial edemas with various degrees of severity. The 
larvae shown in panel A is classified as severe edema and therefore assigned 2 points in the disease score 
system. The larvae shown in panel B has a moderate edema and therefore scores 1 point. The larvae shown in 
panel C has not developed pericardial edema, and is therefore assigned 0 points. Scale bar represents 0.5 mm. 
 
3.5.3 Culturing Mycobacterium marinum 
 M. m was cultured and prepared for infection of zebrafish larvae as outlined in [102, 
112]. M. m transformed with a plasmid coding for the red fluorescent protein dsRed and 
kanamycin resistance (msp 12::dsRed2, gift from Lalita Ramakrishnan, University of 
Washington, Seattle, WA, USA) was kept at 30-32 °C in a dark room in an incubator with a 
shaking stage. Liquid culture medium was prepared using Difco Middlebrook 7H9 broth 
supplemented with 0.02% glycerol, 10% ADC (albumin, dextrose, catalase) and 0.05% 
Tween 80. Kanamycin (Sigma-Aldrich, St. Louis, MO, USA) was added at 50 µg/ml to select 
for fluorescent M. m. To start new liquid culture, either a single colony picked from an agar 
plate or an aliquot taken from frozen stock was added to full 7H9 media as described for 
BCG in section 3.3.6. Bacterial properties change during freezing and thawing [112], 
therefore using bacteria directly from frozen stock was avoided. Stocks were instead allowed 
to recover for a few days and were sub-cultured once before use.  
 
3.5.4 Processing Mycobacterium marinum for microinjection 
On the day of the infection, bacteria were harvested in the exponential phase, OD600 of 
0.5-0.9. Prior to OD600 measurement the culture was re-suspended twice using a 22-gauge 
needle and 20ml syringe to disrupt any bacterial aggregates. A 1.5ml sample of the 
exponential culture was centrifuged at 5000 rpm (2400×g) and the bacterial medium was 
removed. In order to minimize clogging of the bacteria in the microinjection needle, the 
culture was re-suspended in 2% PVP and passaged through a 27-gauge needle 10 times. After 
re-suspension the OD600 was measured again to ensure a final OD600 of 0.9, which 
corresponds to 5.09×107 CFU/ml. When injecting 2 nl, this gives approximately 50 bacteria, 
which establishes a moderate infection, suitable for survival studies. In 500µl bacterial 
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solution, 50µl 2% (w/v) phenol red (Sigma-Aldrich, St. Louis, MO, USA) was added to 
visualize the inoculation and easily identify unsuccessful injections.  
 
3.5.5 Preparation of treatment solution for in vivo survival studies 
Freeze dried PLGA-TZ NPs were stored at 4°C until needed. On the day of the 
injection, NPs were re-suspended in 2% PVP to a final concentration of 15 mg/ml. In order to 
make a homogenous NP solution, this suspension was sonicated 2-5 minutes in a bath 
sonicator and checked periodically in a light microscope to ensure the absence of large 
visible aggregates. The PLGA-TZ NPs have 26.54% loading, so a solution containing the 
corresponding amount of free TZ was also made, with 3.981 mg/ml of the water soluble TZ-
hydrochloride in 2% PVP. Thus the same volume was injected for both free and encapsulated 
PLGA-TZ. For the mock injections 2% PVP alone was used. Phenol red was not added to 
these solutions for visualization of the injection, because this caused the TZ to precipitate and 
clog the microinjection needle. 
 
3.5.6 Zebrafish microinjection 
The following procedure was adapted from Cosma et al. [102]. On 2 dpf the embryos 
are sufficiently developed to allow injection with either M. m or NPs re-suspended in 2% 
PVP. Prior to injections, embryos were kept in sterile embryo water and stored at 28°C. At 1 
dpf, embryos were either dechorionated manually and washed thoroughly and screened to 
ensure that they were properly developed and healthy. 
Microinjection needles were made using borosilicate capillaries (outer diameter 1.0 
mm, inner diameter 0.78 mm, length 100 mm, Harvard Apparatus, Holliston, MA, USA) in a 
Flaming/Brown P-97 micropipette-puller (Sutter, Novato, CA, USA) with the settings: delay 
110, heat 610, pull 40, velocity 50 and pressure 500. Using a micro-loader pipette tip, a 
microinjection needle was loaded with dsRed M. m or treatment solution and mounted on a 
micromanipulator (Narishige, Tokyo, Japan). The needle is attached to a pressure controller 
(Femtojet; Eppendorf AG, Hamburg, Germany), which produces a defined pulse of nitrogen 
leading to a precise injection volume. To calibrate the ejected volume, the needle opening 
size as well as the pressure and duration of the injection were adjusted until the desired 
volume of injection was reached. To do this, the tip of the needle was carefully broken off 
using fine jewelers forceps (Dumont No. 5) before injecting into mineral oil (Sigma-Aldrich, 
St. Louis, MO, USA) and measuring the diameter of the resulting droplet at 59.9× using an 
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arbitrary scale printed on the inside of the ocular. We have previously measured the size of 
the droplet using a 1 cm ruler at this magnification, as shown in Figure 3.5, and can therefore 
use this to determine the volume injected by the diameter of the drop produced. 
 
Figure 3.5: Relationship between drop diameter and volume at 59.9x magnification. Labels on the curve 
represent volume in nl. 
 
The embryos were sedated by immersion in 230µg/ml tricaine stock solution (see 
appendix, supplementary recipes) in embryo water for 2 minutes. The sedated embryos were 
positioned on a 2% (w/v) agarose (Sigma-Aldrich, St. Louis, MO, USA) injection plate using 
a transfer pipette, and excess water was removed to immobilize the larvae during injection. 
Both bacteria and NPs were administered by injecting into the posterior cardinal vein or at 
the yolk circulation valley, as shown in Figure 3.6. The injected embryos were immediately 
placed in fresh embryo water to recover from sedation.  
 
 
 
 
 
Figure 3.6: Injection sites in the zebrafish. Figure adapted from Cosma et al.  [102]. CV= caudal vein. YCV= 
yolk circulation valley. 
 
3.5.7 Embryo survival experiments 
Zebrafish embryos were prepared for infection with dsRed M. m on 2 dpf as described 
above. Control embryos were injected with 2% PVP mock treatment instead of bacterial 
suspension. The injected embryos were allowed to recover over night in fresh embryo water. 
The next day, at 3 dpf, embryos were again injected with PLGA-TZ NPs, empty PLGA NPs 
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or mock injections. The different groups were separated in a 6-well plate. For the drug baths, 
a stock solution of 10 mg/ml RIF was made. To completely dissolve RIF in the embryo 
water, it was first dissolved in 20% DMSO, such that the final concentration of DMSO in the 
embryo water was 0.004% by volume. The groups that were not given the RIF bath treatment 
were kept in embryo water with 0.004% DMSO only. All embryo water was changed daily 
for the duration of the experiment. At 6 dpf, when the larvae initiate feeding, rotifers were 
given to all groups.  
PLGA-TZ NPs were prepared as described above. In the first experiment 3 nl of the 
15 mg/ml stock solution was injected, corresponding to 12 ng TZ by drug weight. Larvae 
typically weigh around 1 mg, so this corresponds to about 12 mg/kg. However, this dose did 
not have much of an effect and was therefore increased to 32.6 ng of TZ, approximately a 
dose of 32 mg/kg, which corresponds to the amount used by Van Soolingen et al. [85] to 
significantly reduce CFUs and show a synergistic effect with RIF in a TB mouse model. 
Therefore, in the second experiment, 8.2 nl of stock solution was injected (summarized in 
Table 3.4). To inject these amounts, the drop-size was calibrated to 0.9 and 1.5 at 59.9×, in 
accordance with Figure 3.5.  
 
Table 3.4: Therapeutic doses of PLGA-TZ injected in zebrafish larvae in the first and second survival 
experiments 
 
Experiment 
Volume injected 
15 mg/ml stock 
Size of drop at 
59.9× 
Amount of  
PLGA-TZ 
Amount of  
free TZ 
1 3.0 nl 0.9 45 ng 12.0 ng 
2 8.2 nl 1.5 123 ng 32.6 ng 
 
3.6 Statistics 
All statistical analysis was preformed in GraphPad Prism 6 software (GraphPad Software, La 
Jolla, CA, USA). In all cases, post-hoc tests for multiple comparisons were only run only 
after confirming overall significance of the test in question. Results obtained in the CCK 
assay, the disease-score and heart-rate analysis were analyzed by an unmatched one-way 
analysis of variance (ANOVA), with Turkey’s post-hoc test for multiple comparisons, 
comparing individual time-points separately. The CFU time-kill assay was analyzed using an 
unmatched two-way ANOVA with Turkey’s post-hoc test for multiple comparisons, 
comparing individual time-points separately. As opposed to the one-way ANOVA, this tests 
the influence of two independent factors on the CFU value, in this case treatment over time. 
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In the overall analysis, significance in each of these factors is assessed, as well as the 
”interaction” between them. If this interaction is not significant (P>0.05), the two factors 
tested influence the measured variable independently of each other. On the other hand, if 
there is a significant interaction (P<0.05), this means that the various treatment groups 
change differently over time, and that the two factors influence each other. Correlation 
between CFU and luciferase assays was done using a parametric two-tailed Pearson 
correlation analysis. Survival studies were analyzed using a Kaplan-Meier representation and 
Log-rank (Mantel-cox) test with a Bonferroni correction (for n=3, p<0.0170 for statistical 
significance) for the comparison of pairwise curves. This procedure compares entire curves, 
not individual time points as ANOVA does. 
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4 Results 
4.1 Synthesis and characterization of nanoparticles 
4.1.1 Encapsulation of coumarin-6 and rifampicin 
Our group has previously established a protocol for the preparation of fluorescent NPs 
and RIF-loaded NPs by single emulsion using the PLGA polymer [114, 123]. For the 
purposes of this thesis, new batches of RIF NPs and fluorescent green coumarin-6 NPs were 
made according to this protocol, as summarized in Table 4.1.  
 
Table 4.1: Summary of preparation method and components of NPs made either with the green fluorescent dye 
coumarin-6 or the standard anti-TB drug RIF. Drug-loading was determined by HPLC, n=3. The amount of 
PVA used in each case is given as percent weight/volume (% w/v).  
 
Method Polymer PVA (% w/v) Dye/drug Drug loading (%) 
Single emulsion PLGA (50:50) 1 Coumarin-6 (green) - 
Single emulsion PLGA (50:50) 1 Rifampicin 31.8 
 
4.1.2 Encapsulation of thioridazine 
Although a former PhD student in the lab had previously made PLGA-TZ NPs, the 
loading achieved was relatively low, at 16%, necessitating large quantities of NP to achieve 
therapeutic dosing. In an attempt to increase the loading, different parameters were tested, 
including method of preparation, polymer type and amount of PVA. Due to its 
biodegradability, we have previously used mostly PLGA (50:50) to make both RIF and TZ 
NPs. However, as TZ is more hydrophobic than RIF, polymers with higher ratios of lactic 
acid to glycolic acid, PLGA (75:25) and PLA only, were tested. The amount of PVA was also 
varied. Drug loading was determined by HPLC (Table 4.2). 
 
Table 4.2: Summary of preparation methods and NP components tested for optimal encapsulation of TZ. Drug 
loading was determined by HPLC, n=3. The amount of PVA used in each case is given as percent 
weight/volume (% w/v). 
 
 
 
 
 
 
 
Method Polymer PVA (% w/v) Drug loading (%) 
Single emulsion PLGA (50:50) 1 25.9 
Single emulsion PLGA (50:50) 4 26.5  
Single emulsion PLGA (75:25) 1 39.7 
Single emulsion PLA 1 27.1 
Nano-precipitation PLGA (50:50) 1 25.3 
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The NPs with the highest drug loading were prepared with the more hydrophobic 
PLGA (75:25) polymer, with 39.7% encapsulated TZ. However, these NPs were impossible 
to re-suspend in water, so they were not suitable for in vitro cell work or in vivo injections. 
This was also the case for the PLA NPs and the NPs prepared by nano-precipitation. The 
standard method of single emulsion, using the same PLGA (50:50) polymer as before, 
produced the best NPs for experimental use. Ultimately, with the exception of the choice of 
polymer, none of the parameters tested greatly affected the encapsulation of TZ. Most of the 
NPs had a loading of approximately 25-27%. As might be expected, the TZ NPs with 4% 
PVA were the easiest to re-suspend, and were therefore chosen for subsequent experiments. 
 
4.1.3 Nanoparticle characterization and imaging 
The PLGA-RIF and PLGA-TZ NPs that were to be used for toxicity and treatment 
experiments were re-suspended in water and characterized using a Zetasizer to measure their 
average diameter and surface charge. The results are shown in Table 4.3.  
 
Table 4.3: Characterization of PLGA-RIF and PLGA-TZ NPs as measured by the Zetasizer, including size and 
size variation (PDI), surface charge and drug loading. NPs were re-suspended in distilled water prior to 
measurement. PDI= polydispersity index. Sizes are expressed as mean ± standard deviation (SD), n=3.  
 
 
NP components Zeta potential ± SD 
(mv) 
Diameter ± SD  
(nm) PDI 
Drug loading 
(%) 
PLGA-RIF NP PLGA 50:50, 1%PVA -20.7 ± 0.7 488 ± 85 0.2 31.8 
PLGA-TZ NP PLGA 50:50, 4%PVA -14.2±0.8 550 ± 72 0.3 26.5 
 
The PDI is a dimensionless quantification of the particle size distribution. A greater 
tendency to aggregate can make NPs appear more poly-dispersed, and a high PDI therefore 
indicates that NPs are more unstable in solution. Typically, the PDI should not exceed 0.7 for 
PLGA NPs, as this can indicate the presence of dust, contamination or aggregation of 
particles [130]. The NPs characterized here have a low PDI. In addition, they have a 
relatively high negative charge, which also means they will have a lower tendency of 
aggregating. They are also within the favorable size-range for macrophage phagocytosis (100 
nm-3µm) [116, 142]. To further characterize NPs, the coumarin-6 NPs were imaged by 
fluorescence microscopy to confirm the encapsulation of green dye, as shown in Figure 
4.1A. Imaging in the transmission EM was also carried out to visualize the NPs in the sample 
and to give a more qualitative evaluation based on size, shape, degree of aggregation and 
extent of polydispersity. The coumarin NPs were green fluorescent, and upon closer 
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inspection in the EM, they were round, relatively mono-disperse and displayed no 
aggregation, as shown in Figure 4.1B. 
 
 
 
 
 
 
 
 
 
Figure 4.1: Coumarin-6 NPs imaged in the fluorescence microscope (A) and the transmission EM (B). Scale 
bars for fluorescence image and EM represent 100 µm and 2 µm, respectively. 
 
 
The remaining TZ NPs that could be re-suspended in water were also imaged in the 
EM. There was no visible difference between batches (Figure 4.2), but we can say that these 
particles were also round, relatively mono-dispersed and displayed no visible aggregation. 
Relative NP size can also be measured by looking at the EM images, and this was done for 
some of the particles (Table 4.4). The mean size estimated by EM was less than half of the 
mean size established by the Zetasizer.  
 
 
 
 
 
 
 
 
Figure 4.2: Transmission EM images of PLGA-TZ NPs prepared by nano-precipitation with 1% PVA (A) and 
PLA-TZ NPs prepared by single emulsion with 1 % PVA (B). Scale bars in A and B represent 5 µm and 2 µm, 
respectively. 
 
Table 4.4: Size estimation by EM of PLGA-coumarin-6 and PLGA-TZ NPs. Sizes are expressed as mean 
diameter ± standard deviation (SD). N= number of individual measurements. 
 
 NP components Diameter ± SD N 
PLGA-coumarin-6 NP PLGA (50:50), 1% PVA 299.03±214.18 20 
PLGA-TZ NP PLGA (50:50), 4% PVA 220.45±107.46 12 
A B 
B A 
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4.2 Optimization of primary cell culture 
In pilot experiments with primary murine macrophages, the cell morphology was 
unexpectedly elongated and fibroblast-like. This led us to question whether the macrophages 
were properly differentiated, and so we tried changing the concentration of M-CSF and 
testing for macrophage characteristics. In order to evaluate how different levels of the 
recombinant M-CSF cytokine affected cell viability, cells were incubated in media 
supplemented with 0-40 ng/ml M-CSF, and measurements using the CCK-8 assay were taken 
at 1, 3 and 6 days (Figure 4.3). After 1 day of incubation, the cells with no M-CSF were 
significantly more viable than those in all other groups. This trend was reversed at 3 and 6 
days, showing instead a dose-dependent increase in viability. However, the cells treated with 
5 ng/ml M-CSF did not show any significant difference from untreated cells at 3 or 6 days. 
 
Figure 4.3: Cell viability in primary murine macrophages incubated in different concentrations of recombinant 
M-CSF, measured by the CCK-8 assay (n=3). A450 values are expressed as mean ± 95% confidence interval. 
Asterisks represent significant difference from untreated cells, as determined by one-way ANOVA in GraphPad 
Prism 6, * P < 0.05, ** P < 0.01 and **** p < 0.0001. 
 
Cells treated with different amounts of M-CSF also changed morphology after 3 days 
of incubation. Wells without M-CSF had more detached cells, and the attached cells looked 
0 n
g
5 n
g
20
 ng
40
 ng
0.0
0.1
0.2
0.3
0.4
A
45
0
Day 1
** **
*
0 n
g
5 n
g
20
 ng
40
 ng
0.0
0.1
0.2
0.3
0.4
A
45
0
Day 3
**
****
0 n
g
5 n
g
20
 ng
40
 ng
0.0
0.1
0.2
0.3
0.4
A
45
0
Day 6
****
****
	   43	  
more rounded, indicating decreased viability. As the concentrations of cytokine were 
increased, the cells looked healthier but also more elongated and fibroblast-like. This was 
especially prominent at the highest concentration, 40 ng/ml M-CSF, which is the 
concentration that had been previously used in our group, and which we have used for 
subsequent studies in this thesis. 
Another factor which affected macrophage morphology was the surface treatment of 
the culture dishes. Surface treatment makes the dish hydrophilic and negatively charged when 
in contact with cell media [131]. This makes it easy for adherent cells to attach and grow.  
Monocytes have a relatively high binding affinity, and therefore do not neccesarily require 
this kind of treatment in order to grow. Treated dishes yielded cells with elongated 
morphology, whereas untreated dishes gave more rounded cells. The same phenotype was 
seen regardless of the source of M-CSF used for differentiation, recombinant M-CSF or 20% 
L929 conditioned media (Figure 4.4).  
 
Figure 4.4: Stereomicroscope images of 2-week old primary murine macrophages differentiated by incubation 
in 40 ng/ml of the recombinant M-CSF (rmM-CSF) cytokine (A and B) or 20% L929 (C and D) on a cell culture 
treated dish (A and C) and an untreated bacterial dish (B and D). Scale bar represents 200 µm. 
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To further evaluate if the macrophages were properly differentiated, we tried to 
evaluate typical macrophage traits including testing for the macrophage surface marker 
CD14, and testing their phagocytotic ability. First of all, CD14 expression was tested by 
immunolabeling and confocal imaging. The primary murine macrophages were positive for 
CD14 (red fluorescence) in 96-100% of the cells (Figure 4.5A). As a positive control, we 
also labeled the mouse RAW macrophage cell line, which also had the CD14 signal (Figure 
4.5B). The negative control (no primary antibody) did not show any specific labeling (Figure 
4.5C). 
 
Figure 4.5: Macrophage characterization by CD14 staining. Primary murine macrophages (A) stained with 
CD14 (red) and Hoechst to visualize nuclei (blue). RAW cells used as positive control (B) and negative control 
in absence of primary CD14 antibody (C). Scale bar represents 50 µm.  
 
 A defining characteristic of macrophages is their strong phagocytic activity. We 
therefore tested macrophages for their ability to take up NPs by incubating them with green 
fluorescent PLGA-coumarin-6 NPs. Fluorescence confocal microscopic analysis showed 
intracellular NPs in all cells (Figure 4.6).  
 
Figure 4.6: Test of macrophage phagocytic activity by means of fluorescent NP uptake. Cells were imaged in 
the confocal microscope. Scale bars represent 50 µm. 
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4.3 In vitro CCK toxicity assay 
Cell viability was quantified following treatment of primary murine macrophages 
with equal concentrations of free and encapsulated PLGA-TZ (2.5, 5.0 and 7.5 µg/ml) for a 
total of 9 days, with measurements at day 3, 6 and 9. Already from day 3, the cells in 
conditions with higher concentrations of free TZ were visibly changed to a more rounded 
morphology and many were detached. However, the encapsulated form of the drug did not 
affect the cells in this way at the same concentrations of drug. Results are summarized in 
Figure 4.7. 
The two highest concentrations of encapsulated TZ (5 and 7.5 µg/ml) were 
significantly less toxic than their free dose counterparts at both day 6 and day 9 (both p < 
0.0001). The lowest concentration of free drug used, 2.5 µg/ml TZ did not show any 
significant in vitro toxicity compared to untreated cells for the duration of the CCK8 assay. 
The viability of cells treated with free TZ at 5 µg/ml, on the other hand, was significantly 
reduced to only 60% that of controls after 3 days (p < 0.05), and 7% after 6 days (p < 
0.0001), with no viable cells left at the last time-point. Cell viability after treatment with free 
TZ at 7.5 µg/ml was also significantly reduced to 12% after just 3 days (p < 0.0001), with no 
viable cells left already after six days. In striking contrast, throughout the 9 days of treatment 
at the corresponding concentrations of TZ, the viability of all the PLGA-TZ-treated groups 
was not significantly different from untreated cells. This was also the case for treatment with 
empty PLGA NPs and even the combination treatment group, which had a total of 43.8 µg/ml 
NPs (by NP weight), corresponding to 8 µg/ml RIF and 5 µg/ml TZ.  
The low dose of 2.5 µg/ml free TZ caused viability to increase above that of controls 
at day 6 and 9. This is possibly because low levels of toxic substances often stimulate 
metabolic activity in cells. When the concentration of TZ was increased, there followed a 
dose dependent increase in toxicity already at 3 days. However, this toxicity was reduced 
when using the encapsulated form of TZ, indicating that the PLGA NPs were able to shield 
the cells from TZ’s toxic effects. This is most likely due to slow release of the drug.  
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Figure 4.7: Viability of cells in response to TZ as measured by absorbance at 450 nm (A450) using CCK-8 assay 
(n=3). TZ was added to cells at 2.5, 5.0 and 7.5 µg/ml in free form and at corresponding concentrations of the 
encapsulated form (PLGA-TZ). A450 values are expressed as mean ± 95% confidence interval, normalized to 
untreated cells for each time-point. Asterisks represent significant difference from untreated cells, as determined 
by one-way ANOVA in GraphPad Prism 6, * P < 0.05 and **** p < 0.0001. 
 
0
50
100
150
Day 3
*
****
0
50
100
150
A
45
0 
%
 o
f u
nt
re
at
ed
 c
el
ls Day 6
****
****
Untreated
Free TZ
PLGA-TZ
Empty PLGA
Un
tre
ate
d
TZ
 2.
5 µ
g/m
l
TZ
 5.
0 µ
g/m
l
TZ
 7.
5 µ
g/m
l
PL
GA
-TZ
 2.
5 µ
g/m
l
PL
GA
-TZ
 5.
0 µ
g/m
l
PL
GA
-TZ
 7.
5 µ
g/m
l
PL
GA
-TZ
 5+
 PL
GA
-R
IF 
25
Em
pty
 PL
GA
0
50
100
150
Day 9
**** ****
	   47	  
4.4 In vitro treatment effect  
4.4.1 Colony forming unit time-kill assay 
The CFU time-kill assay is considered a standard microbiological technique for the 
quantification of bacterial load. This method was used to determine the therapeutic effect of 
our newly synthesized TZ and RIF NPs. PLGA-RIF (at 8 µg/ml by drug weight) and PLGA-
TZ NPs (at 2.5 and 5 µg/ml by drug weight) were tested alone and in combination with each 
other, in primary murine macrophages infected with BCG. One treatment condition used a 
combination of free TZ and free RIF (5 and 8 µg/ml, respectively). In both cases, treatment 
lasted for 3 hours, and no notable toxic effects with respect to morphology and cell 
attachment were seen in any of the treatment conditions, including free drug-treated wells.  
Results of the CFU analysis are shown in Figure 4.8, and only statistical significance 
at the last time-point is shown, to emphasize the overall treatment effect. A two-way 
ANOVA analysis revealed that there was a significant interaction (p< 0.0001) between the 
two variables, indicating that the treatments change differently relative to each other over 
time.  
Unlike previous CFU experiments in our group, which show a steady decrease in 
bacterial load in untreated controls and all treatment groups [123], all groups in the 
experiment presented here showed net growth of bacteria at the final time-point. The 
different conditions seem to be separated into two distinct populations: those that were RIF-
treated and those that were not. All conditions treated with RIF, whether free or encapsulated, 
had an initial drop in CFUs not seen in conditions lacking RIF. However, this initial drop did 
not last beyond 3 days, and in all samples the BCG started growing again after day 3 and 
continued to grow until the end of the assay. Treatment using PLGA-TZ NPs alone, at both 
high and low doses, had a significantly reduced BCG load at the final time-point. 
Furthermore, the combination treatment using 8 µg/ml PLGA-RIF and 5 µg/ml PLGA-TZ 
was significantly more effective at killing BCG than the PLGA-RIF treatment alone at day 3. 
At day 9, both the combination treatments using RIF NPs and 2.5 or 5 µg/ml of TZ NPs were 
significantly better (giving a 2-fold greater reduction of CFUs) than the PLGA-RIF alone.  
The free RIF- free TZ combination treatment was also much more efficient than 
expected. Free drugs were added only once for 3 hours, before cells were washed twice with 
PBS and given fresh media. Despite this, the free drug combination treatment was 
comparable in efficiency to the NP combination treatments. At day 3, free drug treatment 
even appeared to be more effective at lowering CFUs than the corresponding concentration of 
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encapsulated drugs, although this difference was not significant. However, at day 9, free 
drugs did give slightly higher CFUs than their NP counterparts, although this was not 
considered significantly different.  
This experiment was also adapted for enumerating bacterial load using the M. tb 
strain H37Rv in human macrophages by our collaborator David Pires in Elsa Anes’s group 
(University of Lisbon, Lisbon, Portugal). Data from this experiment is shown in Figure 8.1 
in the appendix, under supplementary results. 
 
Figure 4.8: Colony forming unit assay using encapsulated PLGA-TZ NPs (at 2.5 or 5 µg/ml in drug weight) and 
PLGA-RIF NPs (at 8 µg/ml in drug weight) or free TZ and RIF (at 5 and 8 µg/ml in drug weight respectively). 
Treatment duration was 3 hours for both NP and free treated conditions (n=3). Values are given as mean log 
CFU/ml ± 95% confidence interval. Asterisks represent statistical significance, as determined by two-way 
ANOVA in GraphPad Prism 6, * p < 0.05, ** p <0.001, **** p < 0.0001. 
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coefficient of determination (r2 ) can also be computed, where r2 represents the proportion of 
the data whose variation can be explained by the linear relationship between x and y. The 
analysis gave an r of 0.999 (P= 0.00004) for both pairs, and thus an r2 of 0.998 (99.8%), 
indicating a high degree of correlation (Figure 4.10). 
An initial infection OD600 of 0.05 corresponds to 5x106 BCG to which the 
macrophages were exposed for 3 hours. However, the number of CFUs extracted 24 hours 
later was 7.6-fold lower than initial number of CFUs used for infection, likely due to the loss 
of bacteria during infection or the lysis procedure. Lysis of the macrophages infected with the 
lowest infection OD600 of 0.0005 only yielded approximately 1300 bacteria after 24 hours, 
which is more than 38-fold less than the initial level of infection.  
 
Figure 4.9: Bacterial quantification of BCG-lux by parallel experiments using two different methods: 
traditional CFU enumeration and the luciferase assay. Values are expressed as mean ± 95% confidence interval.  
Figure 4.10: Graphical representation (linear regression) of the coefficient of determination (r2) between the 
CFU and luciferase quantification methods, which represents the strength of their correlation.  
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4.5 In vivo toxicity analysis 
4.5.1 Toxicity indicators in zebrafish larvae  
To determine TZ’s toxicity in vivo, free TZ and encapsulated PLGA-TZ NPs was 
injected into zebrafish larvae at 3 dpf at the dose used for survival studies, 32 mg/kg. 
Strikingly, free TZ in larvae immediately caused the heart to stop beating, and in some cases, 
it did not start beating again for more than 60 seconds, while in others it did not start beating 
again at all. In fact, one fourth of the larvae injected with free TZ did not survive the 
treatment on the first day, while all the fish in the NP-injected or mock-injected groups 
survived for at least the first 4 days after treatment. In fact, the overall survival of the NP-
treated larvae was not considered significantly different from the mock-treated larvae 
(p=0.1410) but was significantly different from the survival of larvae treated with free TZ 
(p< 0.0001) as shown in Figure 4.11. Of the fish treated with free TZ that did survive, by 4 
days post treatment (dpt) 5 out of 6 had severe edemas (see edemas in Figure 4.14), all 6 
lacked swim bladders and 3 out of 6 had yolk sac discoloration (see summary of 
morphological indicators in Table 8.1 in appendix, supplementary results). By these 
morphological indicators, the NP-treated larvae were not particularly different from mock-
treated larvae, as seen in Figure 4.14. To quantify this, a disease score was calculated. The 
mean scores assigned to each group were plotted in a scatter plot, shown Figure 4.12. In 
terms of disease score, the mock-treated fish were not considered significantly different from 
the PLGA-TZ treated group, but the free TZ-treated group scored significantly higher than 
the mock and PLGA-TZ treated groups (p< 0.0001 and (p< 0.001 respectively). 
In addition, the heart-rate in larvae injected with free TZ was also slowed to almost 
half of the mock-treated group, while the heart-rate of PLGA-TZ-injected group was not 
significantly different from the mock-treated group (Figure 4.13). For simplicity, only 
significance at 1 dpt is shown in Figure 4.13. However, at 3 dpt the heart-rates of mock-
treated and PLGA-TZ-treated groups were still not significantly different, whereas the heart-
rate of the free TZ-treated group was significantly different to both mock-treated (P<0.01) 
and to PLGA-TZ-treated larvae (P<0.05). Judging from these results and results in Figures 
4.11-4.14 the overall health of the PLGA-TZ-treated group was comparable to that of the 
mock-treated group. 
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Figure 4.11: Survival of zebrafish larvae injected with 32 mg/kg free TZ or corresponding amounts of PLGA-
TZ in 2% PVP. Mock-injected larvae were injected with the same volume of 2% PVP only. Survival curves 
representing mock-injected and PLGA-TZ injected larvae were not significantly different (p=0.1410). Asterisks 
represent statistical significance, as determined by survival analysis in GraphPad Prism 6, **** p < 0.0001. 
(Initial n= 15, 13 and 6 for free, NP and mock respectively) 
 
 
 
 
 
Figure 4.12: Scatter plot representing disease score at 4 dpt of zebrafish larvae injected with free TZ or PLGA-
TZ at 32 mg/kg in 2% PVP. Mock-injected larvae were injected with the same volume of 2% PVP only. The 
disease score was calculated by assigning values to morphological toxic indicators as outlined in Table 3.3. 
Each symbol represents the score of individual larvae, and the horizontal line represents the mean. Error bars 
denote the 95% confidence interval. Asterisks represent statistical significance, as determined by one-way 
ANOVA analysis in GraphPad Prism 6, *** p < 0.001, **** p <0.0001. (n= 6, 13 and 6 for free, NP and mock 
respectively) 
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Figure 4.13: Heart-rate quantification in zebrafish larvae injected with 32 mg/kg free TZ or corresponding 
amounts of PLGA-TZ in 2% PVP. Mock-injected larvae were injected with the same volume of 2% PVP only 
Heart-rate is given in mean beats per minute (bpm) ± 95% confidence interval. Heart rates of mock-injected 
larvae were not considered significantly different from PLGA-TZ injected larvae. Asterisks represent statistical 
significance, as determined by one-way ANOVA analysis in GraphPad Prism 6, *** p <0.001, **** p <0.0001. 
For simplicity only significance at 1 dpt is shown (n= 11, 13 and 6 for free, NP and mock respectively at 1 dpt 
and n=7, 13 and 6 for free, NP and mock respectively at 3 dpt). 
 
 
 
 
Figure 4.14: Morphological comparison of larvae at 2 dpt (4 dpf) after injection of free TZ, encapsulated 
PLGA-TZ, or mock treatment. Following treatment, free TZ-injected larvae developed pericardial edemas and 
necrotic spots not seen in PLGA-TZ-injected fish at the same dose of TZ (32 mg/kg). Scale bar represents 0.5 
mm. 
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4.6 In vivo combination therapy  
4.6.1 Treatment using injected PLGA-TZ NP at 12 mg/kg and RIF bath  
In addition to reducing toxicity, NP treatment may make drug delivery more efficient. 
However, the toxic nature of TZ at the concentrations used for treatment makes it difficult to 
directly compare free and encapsulated forms of the drug. Therefore, PLGA-TZ NPs were 
used in all in vivo treatment experiments. 
TZ therapy was tested in vivo in zebrafish infected with M. m at 2 dpf and injected 
with PLGA-TZ NPs or mock-injections at 3 dpf. Free TZ was not used due to the high 
toxicity of the treatment dose. Combination treatment was tested by adding free RIF to the 
embryo water at 200 µg/ml (instead of injecting RIF), to avoid potential harmful effects from 
multiple injections. In the first survival experiment, 3 nl of PLGA-TZ NPs solution was 
injected in larvae, corresponding to a treatment dose of 12 mg/kg. Survival was recorded 
daily and results are shown in Figure 4.15. Unlike the synergistic tendency seen in the in 
vitro data, the PLGA-TZ/RIF combination treatment was not significantly different from RIF 
treatment alone (p=0.8622). Furthermore, PLGA-TZ treatment alone was not significantly 
different compared to the mock treated larvae (p=0.4478). Unsurprisingly, treatment with 
RIF bath alone significantly improved survival compared to mock treated larvae (p=0.0015).  
 
Figure 4.15:  Survival of zebrafish larvae (n=16-18) injected with 12 mg/kg PLGA-TZ in 2% PVP or mock 
injected with 2% PVP only, and treated with 200 µg/ml RIF bath or embryo water only. Survival curves 
representing the PLGA-TZ/RIF combination treatment were not significantly different from RIF bath treatment 
only (p=0.8622). PLGA-TZ treatment alone was also not significant compared to mock treated larvae 
(p=0.4478). Asterisks represent statistical significance, as determined by survival analysis in GraphPad Prism 6, 
** p < 0.01 
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4.6.2 Treatment using injected PLGA-TZ at 32 mg/kg and RIF bath 
The experiment outlined in the section above was repeated, but this time the dose of 
TZ was increased to 32 mg/kg, which has previously been shown to potentiate therapy in a 
mouse model of TB [85]. The results are shown in Figure 4.16. In this experiment, the 
increased dose of PLGA-TZ combined with the RIF bath significantly increased the survival 
of the larvae compared to RIF bath treatment alone (p=0.0027). However, the PLGA-TZ 
treatment alone did not significantly increase larvae survival, unlike the in vitro results.  
The last surviving larvae from the PLGA-TZ/RIF bath combination group and the 
RIF-bath treated only group were also imaged in the fluorescence microscope at 11 dpt to 
estimate the relative bacterial burden (Figure 4.17). The larvae that received PLGA-TZ/RIF 
bath combination treatment had reduced visible fluorescent bacterial load relative to larvae 
treated with RIF bath only, suggesting that the combination treatment was more efficient. In 
fact, one individual receiving combination treatment showed almost complete clearance of 
the fluorescent bacteria.  
The experiment was repeated a second time using the same dose of PLGA-TZ NPs 
(32 mg/kg) and RIF bath treatment. In order to see what contribution the PLGA component 
of the NPs had on therapy, a combination treatment using injection of empty (drug-free) 
PLGA NPs with RIF bath was also included (Figure 4.18). Again, the PLGA-TZ/RIF bath 
combination treatment significantly improved survival relative to treatment with RIF bath 
alone (p=0.0146), while PLGA-TZ therapy alone was not significantly different from mock 
treated larvae (p=0.8043). Interestingly, combination treatment with injected drug-free PLGA 
NPs and a RIF bath was not significantly different from either PLGA-TZ/RIF bath 
combination treatment (p=0.1452) or RIF bath alone (p=0.2386). 
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Figure 4.16:  Survival of zebrafish larvae (n=15-17) injected with 32 mg/kg PLGA-TZ in 2% PVP or mock 
injected with 2% PVP only, and treated with 200 µg/ml RIF bath or embryo water only. Survival curves 
representing the PLGA-TZ/RIF bath combination treatment were significantly different from RIF bath treatment 
alone (p=0.0027). However, PLGA-TZ treatment alone was not significant compared to mock treated larvae 
(p=0.3483). Asterisks represent statistical significance, as determined by survival analysis in GraphPad Prism 6, 
** p < 0.01, **** p < 0.0001. 
 
 
Figure 4.17: Zebrafish larvae at 9 dpt (11 dpf) infected with dsRed M. m and treated with either 200 µg/ml RIF 
bath only (left) or a combination treatment with 32 mg/kg PLGA-TZ injections and 200 µg/ml RIF bath (right). 
Larvae were imaged in the fluorescence microscope. Scale bar represents 0.5 mm. 
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Figure: 4.18:  Survival of zebrafish larvae (n=15-17) injected with 32 mg/kg PLGA-TZ in 2% PVP or mock 
injected with 2% PVP only, and treated with 200 µg/ml RIF bath or embryo water only. Survival curves 
representing the PLGA-TZ/RIF bath combination treatment were significantly different from RIF bath treatment 
alone (p=0.0146). Treatment with empty PLGA NPs and RIF bath was not significantly different from either 
PLGA-TZ and RIF bath (p=0.1452) or RIF bath alone (p=0.2386). PLGA-TZ treatment alone was not 
significant compared to mock treated larvae (p=0.8043). Asterisks represent statistical significance, as 
determined by survival analysis in GraphPad Prism 6, * p < 0.05, **** p < 0.0001 
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5 Discussion 
5.1 Preparation of thioridazine nanoparticles 
In order to efficiently encapsulate different drugs like RIF and TZ, the encapsulation 
procedure has to be carefully optimized to match their unique physical properties, such as 
their relative hydrophobicity. With this in mind, a protocol for the encapsulation of TZ in 
biodegradable PLGA NPs was established. For the PLGA NPs to efficiently function against 
M. tb, they must be able to reach intracellular bacteria, inside macrophages. Previous studies 
done in our group have shown that 90% of polymeric NPs can be found in phago-lysosomes, 
whereas BCG were located in early phagosomes inside the same cells [123]. It was expected 
from the outset that the physical characteristics of NPs can make a difference in how 
efficiently NPs are taken up. With this in mind, NPs are made small enough for phagocytosis, 
but also made to have a surface charge in order to be more easily recognized by the 
macrophages that take them up. 
   
5.1.1 Optimization and characterization of PLGA-TZ 
A protocol for the formulation of PLGA-RIF NPs has previously been established and 
tested [114, 123]. By following this protocol, PLGA-RIF NPs were formulated with similar 
drug loading to those prepared previously, approximately 32%. We had not yet optimized the 
formulation of PLGA-TZ NPs, however, and this prompted the evaluation of different 
parameters in order to establish the method best suited for TZ encapsulation.  
TZ is more hydrophobic than RIF, and as might be expected the highest TZ loading 
was achieved with the more hydrophobic PLGA (75:25) polymer, with 1% PVA. However, 
like many of the other NPs, these particles were difficult to re-suspend in an aqueous 
solution. In order to take advantage of the higher loading efficiency achieved with this more 
hydrophobic variety of PLGA, the amount of PVA could be increased to make NPs with 
higher loading that are easier to resuspend in water. The addition of an emulsifier like PVA 
contributes reducing aggregation and lowering surface tension, which increases the solubility 
of the hydrophobic drug in the aqueous phase [143]. It follows that a higher amount of 
emulsifier could also aid the retention of drug in the aqueous phase during NP preparation, 
which may lead to a lower encapsulation. However, varying the amount of PVA from 1 to 
4% in the different PLGA (50:50) NPs did not seem to affect the encapsulation significantly, 
as all the TZ-NPs we made had a loading of 25-27% (Table 4.2). 
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In the end, the TZ NPs with PLGA (50:50) and 4% PVA were chosen for continued 
characterization, as these had the highest loading (26.5%) of the NPs that could be re-
suspended in water. Measurements using the Zetasizer (Table 4.3) revealed that both these 
NPs and the PLGA-RIF NPs had a size distribution range, quantified as PDI, below 0.7 
[130], which indicates that they make up a relatively homogenous suspension and have a 
lower tendency to aggregate. One of the reasons for their lack of aggregation is likely their 
overall negative charge. High NP charge causes electrostatic repulsion between particles, 
making them less likely to aggregate and sediment. Surface charge therefore makes an 
important contribution to solution stability [130]. Furthermore, a negative surface charge also 
leads to increased opsonization (such as binding of IgG or complement factors from serum) 
and rapid macrophage uptake compared to neutral NPs, despite the negative charge of cell 
membranes [116]. In addition, PLGA’s hydrophobic nature is also conducive to binding of 
opsonins [144]. Taken together, these physical properties of NPs make them favorable for 
macrophage uptake, which in turn promotes the bioavailability of the encapsulated drug 
[144]. 
The size of the PLGA-TZ NPs determined by the Zetasizer and EM (approximately 
500 and 200 nm respectively) places them in the range for macrophage phagocytosis (100 
nm-3µm) [116, 142]. In the Zetasizer, size is quantified as the hydrodynamic diameter of 
NPs, which reflects the fact that the measurement is dependent on their speed of diffusion 
through a given solvent. The hydrodynamic diameter depends on the NPs interaction with the 
solvent, which forms a discrete layer on the outside of the NP. In theory, the hydrodynamic 
diameter may therefore be larger than the NP’s diameter in the absence of an aqueous 
environment. The measurement of NP diameter is inextricably linked to the solvent used, as 
the properties of the solvent can have a significant impact on the results. For instance, the 
hydrodynamic diameter of particles can be exaggerated if the medium has low conductivity. 
Conversely, a medium with high conductivity can underestimate the particle size. This is due 
to the conductivity of the medium affecting the diffusion speed of the particles in the solvent, 
which affects the degree of scattering and thus the diameter measurements [130]. The 
measurements reported in Table 4.3 were taken in de-ionized water, which can explain why 
the diameters estimated by imaging in the EM are smaller than those reported by the 
Zetasizer. In addition to diameter, choice of solvent also affects the zeta-potential. This is 
because the zeta-potential represents overall NP charge, which takes into account the layer of 
solvent molecules around NPs in solution and is measured at a small distance from its 
surface. This overall charge can vary from the surface potential of the particle itself due to 
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interactions with the solvent in this discrete layer around the NP [130]. As the measurements 
presented in Table 4.3 were taken in distilled water, a solvent that does not reflect the 
physiological environment, these values may be an inaccurate estimate of the physical 
characteristics in vitro or in vivo. To more realistically and accurately measure NP size and 
charge, it may be better to use a more physiologically relevant solvent, such as an isotonic, 
physiological salt solution (0.9 % w/v NaCl). As described above, size and charge are 
important for cell interaction with NPs in terms of uptake, immunogenicity and clearance 
from the blood stream.  
The size and shape of NPs can also help to localize NPs to certain tissues. This would 
be interesting in the context of TB, as NPs can be made to preferentially accumulate in the 
lung, the main site of TB in humans. In the mouse model for instance, PLGA-NPs of 
approximately 200 and 500 nm injected into the circulation of mammals mostly end up in the 
liver and to a lesser extent in the lungs and spleen, without any active targeting [145]. 
However, increased homing of NPs to the lung can be achieved via actively targeting with 
antibodies, and increased phagocytosis by macrophages can be achieved by making rod-
shaped NPs [146]. An alternative approach is to target NPs or microparticles to the lungs is 
via direct aerosol administration [147].  
 
5.2 The encapsulation of thioridazine reduces toxicity 
Toxicity is a major concern when it comes to the potential use of TZ for the treatment 
of TB [148]. The rate of sudden death due to heart failure is nearly twice as high in patients 
undergoing neuroleptic treatment with TZ compared to the general (untreated) population 
[85]. Using TZ to treat TB in humans will most likely necessitate even higher concentrations 
than those normally used for neurological disorders, which is typically around 8 mg/kg in 
chronically psychotic patients [90]. Judging from both in vitro and in vivo studies performed 
here, however, encapsulation can make TZ less toxic than the free form of the drug. 
 
5.2.1 Thioridazine in vitro toxicity in macrophages 
The results of the CCK-8 toxicity assay show that the encapsulation of TZ 
significantly decreased the toxic effects of free TZ on macrophages. The concentrations 
tested were the same as those used in previous in vitro treatment experiments in our group 
(2.5 and 5 µg/ml TZ). In these experiments, the most promising synergistic effects were seen 
using 5 µg/ml continuously added free TZ in combination with 8 µg/ml PLGA-RIF NPs, 
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which cleared the intracellular infection after 9 days (unpublished data by Raja Kalluru). 
However, there were some indications that this concentration was toxic, noticed both by our 
group and by our collaborators David Pires and Elsa Anes working on human macrophages 
and M. tb. In support of this, it has previously been established that 3 µg/ml free TZ is toxic 
to 50% of macrophages, whereas 10 µg/ml gives 100% toxicity after 72 hours [79]. We 
therefore decided to quantify cell survival using the CCK assay and to see whether high 
concentrations of the drug are less toxic when encapsulated. According to the data presented 
in Figure 4.7, we saw that 5 µg/ml is toxic in the free form but that this toxicity can be 
significantly reduced by encapsulation in concentrations up to (but not limited to) 7.5 µg/ml. 
This result fits well with the widely expressed advantage of NPs in reducing drug toxicity in 
vivo [149]. 
The lowest concentration of free drug used in this thesis (2.5 µg/ml) did not show any 
significant in vitro toxicity for the duration of the CCK8 assay. If anything, the macrophages 
seem to be stimulated by the low dose of TZ, as their dehydrogenase activity was slightly 
higher than in the untreated cells at the last two time-points, although this difference was not 
deemed significant. This issue is addressed in the product trouble-shooting guide of the 
commercial CCK8 assay, which states that low levels of drugs can activate the cells as 
enzymatic activity increases in an attempt to eliminate the toxic substance. This can result in 
higher readings, reflecting an increase in metabolic activity that can be mistakenly interpreted 
as cell proliferation. It is conceivable that this antibiotic-stimulated increase in metabolism 
could be masking any toxic effect from treatment with 2.5 µg/ml TZ. To test this, one could 
use a method that detects cell death as opposed to cell viability, for example the LDH (lactate 
dehydrogenase) assay, which detects LDH, a biomarker released from dying cells [150].  
 
5.2.2 Thioridazine in vivo toxicity in zebrafish 
Injections of free TZ and encapsulated PLGA-TZ caused dramatically different 
phenotypes in the zebrafish larvae in terms of cardiotoxicity, yolk discoloration, edemas, 
swim bladder inflation and overall survival (Figures 4.11-4.14). The cardiotoxic effect of 
free TZ was especially striking, as injection of 32 mg/kg free TZ caused the heart to 
immediately stop beating in all fish. In the larvae that re-gained a heartbeat, there was a 
significant decrease in heart-rate (Figure 4.13). This effect resembles the human symptoms 
of prolonged QT-interval and ventricular arrhythmia following TZ exposure [68, 151]. In 
fact, quantification of toxicity in terms of morphological indicators in zebrafish has 
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previously correlated well with human data [138, 140]. In particular, drugs that are 
cardiotoxic in humans, such as aspirin and verapamil, also induce cardiotoxicity in zebrafish, 
including changes in heart-rate and formation of pericardial edemas. Conversely, drugs that 
manifest their human toxicity in other ways, such as gentamicin and tetracycline, do not 
cause cardiotoxicity in zebrafish [140]. With this in mind, the zebrafish model has been 
deemed excellent for high-throughput screening and prediction of human cardiotoxicity 
[140]. In the case of TZ, encapsulation in NPs clearly reduces this cardiotoxicity, which is a 
prerequisite for the evaluation of TZ’s treatment effect. In contrast to free TZ injections, 
which cause 60% of treated fish to die within four days of treatment, the PLGA-TZ NPs 
make a fair comparison of TZ therapy to other treatments possible. In addition to TZ’s 
cardiotoxicity, another striking effect of injecting 32 mg/kg free TZ in zebrafish was the 
incidence of pericardial edemas. Pericardial edemas occur when an abnormal amount of fluid 
accumulates in the space around the heart chamber. This phenotype is often associated with 
toxicity and can be caused by heart failure or changes in the blood flow, among other things 
[138]. By encapsulating TZ, the incidence of edemas was no longer a problem, and the larvae 
were morphologically indistinguishable from mock-treated fish.  
The inflation of the zebrafish swim bladder, normally used by the fish for generating 
the lift necessary for flotation [152], is also a commonly used toxicity indicator [153]. Lack 
of swim bladder inflation in larvae treated with toxic chemicals often correlates with other 
morphological defects, such as edemas [139]. In order to inflate the swim bladder, larvae 
must achieve “swim-up behavior”, which means they need to reach the surface to gulp the air 
necessary for inflation [152]. In zebrafish larvae, the swim bladder normally inflates within 
96 hpf, which corresponds to 4 dpf [154]. In the toxicity analysis presented here, 4 out of 13 
larvae (or 31%) treated with PLGA-TZ had still not inflated their swim bladders at 4 dpt (6 
dpf). However, this effect is comparable to the mock-treated group where 2 out of 6 larvae 
(or 33%) had still not inflated their swim bladders at 6 dpf. This could indicate a general 
developmental delay in this particular batch of embryos, or reflect that the injection itself had 
some effect in interfering with swim bladder inflation. This illustrates the importance of 
having mock-injected controls for the sake of comparison, but would need to be verified by 
also including a non-injected group in the experiment. On the other hand, none of the larvae 
injected with free TZ at 32 mg/kg were able to inflate their swim bladders. These larvae 
could be failing to inflate their swim bladders due to the direct physiological effects of the 
drug, or indirectly due their general weakened condition causing a lack of “swim-up 
behavior” necessary for the process of inflation.  
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In addition to the morphological changes discussed above, larvae injected with free 
TZ have an overall change in color, which does not occur in mock or PLGA-TZ injected 
larvae. They become darker and develop necrotic spots, especially in the yolk sac. In 
summary, the encapsulation of TZ in PLGA NPs protects zebrafish larvae from the toxic 
effects associated with free TZ, including dramatic morphological changes in zebrafish 
larvae. The PLGA-TZ-injected larvae were comparable to mock-injected larvae in terms of 
heart rate, swim bladder inflation, edemas and yolk discoloration.    
 
5.3 Thioridazine can potentiate rifampicin treatment 
The treatment of TB using TZ is often applied by monotherapy in the literature [74, 
79, 90, 155]. In fact, TZ monotherapy has been suggested as a treatment for XDR-TB [155], 
supported by promising results in infected macrophages [74], in the mouse model [85, 90] 
and in humans receiving compassionate XDR-TB therapy [155]. However, much of the 
experimental data, including our own, on TZ’s therapeutic effect alone and together with RIF 
suggest that, while TZ has a modest effect on its own in vitro, the key lies in using a 
synergistic combination treatment rather than using TZ alone.  
 
5.3.1 In vitro combination treatment using CFU time-kill assay 
Experiments quantifying BCG CFUs following TZ-RIF combination treatment have 
been carried out previously (unpublished data by Raja Kalluru). These showed a steady 
decrease in CFUs in all groups, including the controls, and a clear synergistic effect of RIF 
NPs with free TZ. However, as mentioned above, in these experiments the toxic 
concentration of 5 µg/ml free TZ was added continuously throughout the experiment. It is 
therefore possible that the reduction of CFUs seen in those experiments was partially due to 
the death of macrophages hosting the bacteria, as opposed to death of bacteria themselves. In 
addition, the bacteria used for those experiments were cultured differently, and they were 
most likely not in the logarithmic phase when harvested. We therefore decided to repeat this 
experiment, and the results presented here differ from those previous results in several 
important aspects.  
Firstly, we did not see the characteristic steady decrease in CFUs in any of our 
conditions. Untreated control bacteria grew continuously, and although both free RIF and 
PLGA-RIF-treated bacteria experienced an initial drop, these also started growing at the final 
time point (Figure 4.8). In direct contrast to this result, it has previously been reported that 
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BCG in mouse primary macrophages do not grow intracellularly, but rather show a steady 
decrease in the absence of any drugs. However, in the same study BCG did grow 
intracellularly in RAW macrophages and human primary macrophages [156]. Previous 
results in our group behaved more like the former, whereas the BCG in the results presented 
here behaved more like the latter, exhibiting intracellular growth. This discrepancy could 
reflect differences in culture conditions that influence bacterial growth. 
The conditions used for BCG culture are extremely important for bacterial growth-
state and antibiotic susceptibility. For example, limiting oxygen-supply can induce a non-
replicative, dormant state in M. tb [157] and BCG [158], which makes them less susceptible 
to bacteriostatic drugs, including RIF and INH [47, 48]. Culture conditions can also interfere 
with a recently identified capsular layer in mycobacteria, which aids in virulence and is lost if 
a culture is agitated too much [159]. Bacterial cultures that are agitated regularly, either by 
shaking or in the context of processing for OD measurement, also grow faster than cultures 
that are not agitated. The vessel and volume used for culturing also has an effect, and bacteria 
may sometimes collect at the bottom of the vessel as a pellet. In the end, artificial in vitro 
systems vary a lot, and even the smallest variation in the culture procedure can have a big 
impact on the result.  
The combination treatment using PLGA-RIF and PLGA-TZ showed a synergistic 
effect between the two drugs, reducing BCG burden by 19- and 20-fold with TZ at 2.5 and 5 
µg/ml respectively. This is not an additive effect, as PLGA-RIF NPs alone reduced the 
burden by nearly 10-fold, and PLGA-TZ NPs alone reduced it by 2.5- and 2.8-fold at 2.5 and 
5 µg/ml respectively. However, the contribution of TZ to synergy with RIF was not as 
striking as we have seen in previous experiments. This implies that the PLGA-RIF NPs used 
here were a lot more effective on their own, despite that the parameters such as duration of 
treatment and drug concentrations were kept constant. This could be due to the fact that the 
batch of PLGA-RIF NPs used previously was different, although they had very similar 
loading (approximately 32%). Despite this, the amount of drug that is released from a given 
batch of NPs may be different, either because of different physical-chemical release 
characteristics or because of differences in how the NPs were processed before treatment. 
Release studies on previous batches of PLGA-RIF NPs have been done in our group, 
measuring how much of the drug escapes from the NPs at pH 4, mimicking a lysosomal 
environment, and pH 7, mimicking a physiological environment. These experiments have 
shown that a rapid initial “burst-release” occurs with loss of 60% of the encapsulated drug 
after one day at pH 4, and 80% at pH 7 [123]. The lower release at pH 4 is most likely due to 
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RIF’s reduced solubility at acidic pH [160]. Initial burst release in our NPs is followed by a 
slower release of the remaining drug that lasts for at least 12 days [123].  
Previously in our group, treatment with RIF NPs was shown to be significantly more 
effective than treatment with free RIF. This is the case both in vitro [123] and in vivo [114]. 
On the other hand, in our latest experiment (Figure 4.8), treatment with free TZ and free RIF 
had an unexpectedly potent effect, comparable to treatment with PLGA-RIF NPs. 
Interestingly, at day 3, free drug treatment lowers CFUs more efficiently than the 
corresponding amounts of encapsulated drugs, which might be expected as an initial effect of 
the high dose of free drugs, although this effect was not significant. However, this effect did 
not last beyond the initial time points, as the free drug disappeared when the cell media was 
changed. However, the PLGA-RIF-treated conditions, whether alone or in combination with 
PLGA-TZ, also had a similar drop in CFUs at 3 days, after which they all started growing 
again. This does not fit well with the hypothesis of a prolonged NP treatment relative to free 
drug treatment due to sustained release of drug. This could, however, also be explained by 
the initial burst release effect. If 60-80% of the drug in the NPs is being released as soon as 
they are re-suspended in water, the NP treated cells will also have a relatively high amount of 
free drug in the media, almost approaching the levels of drug in the free drug-treated cells. In 
addition, to properly re-suspend the NPs in treatment media, a brief sonication is necessary. 
This may cause more drug to escape from the NPs, which contributes to the burst release-
effect. In comparison to previous experiments, it is conceivable that the free dose of RIF used 
here was too efficient against our particular strain of BCG under our specific growth 
conditions, and that the burst release caused the level of free RIF in the NP treatment 
condition to be comparable to this free dose. 
While the RIF was being rapidly released from NPs, this is likely not the case with the 
TZ in PLGA-TZ NPs, as this would clearly manifest itself as morphologic toxicity. Since we 
did not see any significant toxicity in the PLGA-TZ-injected larvae, TZ was probably better 
retained in the NPs than RIF was. TZ is more hydrophobic than RIF, and this could explain 
why TZ interacts better with the hydrophobic PLGA polymer. To verify this, release studies 
analogous to those done on RIF NPs would have to be carried out. 
In the literature, drug-susceptible M. tb cultures have a TZ MIC of 15 µg/ml, and 
complete clearance was achieved with 30 µg/ml TZ in the absence of macrophages [74]. 
However, Ordway et al. [74] showed complete clearance of both susceptible and MDR 
intracellular M. tb infections after just three days using TZ mono-therapy at the extremely 
low, non-toxic concentration of 0.1 µg/ml. This striking reduction at such low concentrations 
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of TZ was attributed to a concentrating effect of the drug inside macrophages [72]. However, 
in the results reported by Ordway et al., macrophages were pre-pulsed with TZ for 1 hour 
before they were actually infected. Hence, it is difficult to say if the decrease in bactericidal 
concentration was due to intracellular residence alone, or if pre-pulsing of the drug had an 
additional effect. Although pre-treating macrophages with TZ before infection works 
efficiently in vitro, it does not reflect therapeutic situations in vivo. When comparing our 
results to those of Ordway et al., it is important to remember that, where free drugs where 
used in our model, we used a longer, 3-hour treatment, with a higher concentration of TZ (5 
µg/ml), which was administered after macrophage infection. Still, our treatment, which was 
25 and 50 times higher than the concentrations used by Ordway et al., and administered in 
combination with free RIF (at 8 µg/ml), did not lead to clearance of the infection. The big 
difference seems to lie in the pre-treatment of cells with TZ before they are infected, which 
greatly boosts bacterial killing. 
To our knowledge, there is only one other published study by Adams et al.  [74, 161] 
where the antimicrobial capacity of TZ against M. tb inside macrophages is tested without 
pre-loading. In this paper, TZ improved treatment with RIF (approximately 1.5 fold) and INH 
(approximately 2-fold) following a 48-hour treatment with TZ at 2 µg/ml. However, these 
bacteria were made phenotypically resistant by intracellular residence in macrophages, and 
then released prior to treatment with TZ and RIF. Despite this, the results presented by 
Adams were comparable to the data presented in Figure 4.8, where both NP combination 
treatments (using 2.5 and 5 µg/ml TZ) improved PLGA-RIF NP treatment by 2-fold. 
Similarly, in Figure 4.8 free RIF and free TZ combination treatment were approximately 1.6 
fold better than PLGA-RIF treatment alone, again illustrating the fact that there is little 
difference between the free and encapsulated drugs in terms of efficacy. 
In summary, despite the fact that we were not able to completely clear the infection in 
our system with these higher concentrations of TZ, we did see a significant reduction of 
CFUs at the final time point using PLGA-TZ monotherapy. We also observed a significant 
improvement when using both free and encapsulated TZ/ RIF combination treatment in 
comparison to RIF NP treatment alone, even if this was not different between free and 
encapsulated forms of the drug. In order to improve this treatment, we should increase the 
dose or duration of PLGA-TZ NP treatment in future experiments. However, we will most 
likely not be able to compare these higher doses of PLGA-TZ NPs to their free drug 
counterparts in vitro because, as we saw in the CCK assay, concentrations above 2.5 µg/ml 
are toxic to macrophages when administered continuously. In this respect the encapsulation 
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of TZ is advantageous after all, as it allows us to bring up the concentration of TZ without 
increasing toxicity. 
 
5.3.2 CFU time-kill assay with M. tb and human macrophages 
Our collaborator David Pires, working in Elsa Anes’s lab in Lisbon, Portugal, also 
tested our PLGA-RIF and PLGA-TZ NPs in human macrophages infected with M. tb 
(presented in Figure 8.1 in the appendix, supplementary results). Unlike our BCG CFU data, 
the PLGA-TZ NPs only had a brief effect in killing bacteria on the first day of the assay, after 
which these bacteria grew as fast as the untreated controls, with no reduction in CFUs at the 
last time-point. Despite the fact that PLGA-TZ alone had no significant effect, it did improve 
treatment in combination with PLGA-RIF NPs after day 5, implying synergy between the 
two drugs. In fact, the low dose of PLGA-RIF NPs with the high dose of PLGA-TZ NPs (8 
and 2.5 µg/ml by drug weight respectively) was comparable to the high dose of PLGA-RIF 
NPs alone (16 µg/ml RIF by drug weight) at the final time-point. However, the RIF treatment 
alone was very potent, and therefore reducing this dose may be helpful in determining the 
real contribution of TZ in potentiating RIF treatment.  
We have previously collaborated with David Pires and Elsa Anes to test free TZ in 
combination with PLGA-RIF NPs. During these experiments, the high concentration we had 
tested on BCG in our lab, 5 µg/ml was too toxic to use on primary human macrophages. 
Therefore they used 1.25 and 2.5 µg/ml free TZ instead. When they received the new batch of 
PLGA-TZ NPs from our lab, the same low concentrations were used, which can explain the 
lack of effect in the lowest treatment with PLGA-TZ only. However, while we saw a 
significant reduction in CFUs at the final time-point with 2.5 µg/ml PLGA-TZ NPs against 
BCG, this was not the case for the M. tb-infected human cells, implying that a higher dose of 
TZ may be necessary against this pathogenic strain. In order to test this, the dose of TZ could 
be increased in the future, since the PLGA-TZ NPs provide an opportunity to increase the 
dose of TZ without inducing toxicity. Our collaborators are now working on repeating this 
experiment using a higher dose of PLGA-TZ NPs, and a lower dose of PLGA-RIF NPs to see 
if the synergistic effects can be highlighted.  
 
5.3.3 In vivo combination treatment with TZ and antibiotics 
In the survival experiments conducted herein, initial injection of TZ was done with 
approximately 12 mg/kg TZ encapsulated in NPs, comparable to the concentration used by 
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Dutta et al. [89] in the mouse model. These authors showed no improved effect when using 
free TZ at 10 mg/kg in combination with free RIF at 10 mg/kg, although this dose of TZ did 
have a moderate effect in improving INH therapy [89]. Our results are similar in that this 
dose of PLGA-TZ had no significant effect on its own or in combination with the RIF bath in 
the zebrafish model. In subsequent survival experiments, we therefore increased the dose to 
32 mg/kg (Figure 4.16 and 4.18), which is comparable to what van Soolingen et al.  [85] 
used in the mouse model. This group of authors was able to show that both TZ monotherapy 
and combination treatment using free TZ at 32 mg/kg and free RIF at 10 mg/kg significantly 
improved therapy [85]. We also saw this improved synergistic effect in the zebrafish model 
using combination treatment with 32 mg/kg PLGA-TZ in the RIF bath; while PLGA-TZ 
alone did not improve treatment efficiency, RIF bath treatment alone improved survival by 2-
fold, and treatment with RIF bath and PLGA-TZ injections improved survival 5-fold 
compared to untreated controls (Figure 4.18). In Figure 4.16, there are no untreated fish left 
at the final time point (9 dpt, 11 dpf), but again, while PLGA-TZ alone did not improve 
embryo survival, the combination treatment was 2.3-fold better than RIF bath treatment 
alone.  
Unlike the in vitro data, the survival of larvae treated with our PLGA-TZ particles 
alone at 32 mg/kg was not significantly different from that of untreated controls. These 
experiments were only monitored for 9 dpt, after which conditions were no longer optimal, 
and uninfected controls stared to die. However, in the mouse model, in vivo monotherapy 
with lower doses of free TZ (16 mg/kg) given daily for 300 days has shown an 8-fold 
decrease in bacterial loads, although residual bacteria remained [90]. This implies that TZ 
may be even more effective if we could renew the dose of PLGA-TZ periodically, and 
monitor larvae for longer. To do this we would have to optimize living conditions so 
uninfected control larvae do not start dying after 9 dpt. 
Previous survival experiments in our group have shown an improved effect of 
injecting PLGA-RIF NPs rather than free RIF [114]. This comparison is impossible in the 
case of TZ, as injecting the high dose of free drug necessary for treatment of M. m infection 
is highly toxic to the fish. In order to study combination treatment in the zebrafish larvae, the 
optimal situation would have been to use separate injections of both PLGA-RIF NPs and 
PLGA-TZ NPs. However, this would also be technically difficult to achieve and could 
adversely affect the fish. Instead, we tested a combination of RIF bath with PLGA-TZ NP 
injections, which improved survival relative to RIF bath treatment only.  
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Interestingly, as seen in Figure 4.18, injecting empty PLGA NPs also seemed to 
improve survival in combination with RIF bath, although this was not statistically significant. 
Previous experiments in our group have also shown that empty PLGA NPs slightly (non-
significantly) improved survival of infected embryos, although PLGA-RIF NP injections 
were much more efficient, significantly improving survival [114]. This suggests that PLGA 
itself has an immunogenic effect, and an important question in our experiments is whether 
this putative macrophage stimulation contributes more than the anti-microbial effect of TZ 
itself. In our experiment, PLGA-TZ NPs did not significantly improve survival when 
administered alone, which implies that the TZ component of the NPs has limited therapeutic 
effect beyond what PLGA alone already contributes to survival. On the other hand, based on 
our results and the literature, TZ is more potent in combination treatment; while PLGA-TZ 
injections and RIF bath is significantly better than RIF bath alone, empty PLGA injections 
and RIF bath showed no such improvement. However, it is difficult to make this conclusion 
unequivocally, as the combination treatments with either PLGA-TZ or empty PLGA 
injections were not significantly different from each other. 
 
5.3.4 Can we really call thioridazine an efflux pump inhibitor? 
It is often implied in the literature that TZ mainly functions as an EP inhibitor. This is 
supported by data showing that antibiotic-induced increase in efflux of ethidium bromide by 
BCG bacteria can be blocked by adding TZ [80]. However, TZ is a pleiotropic drug, and 
considering the many effects it has on both bacterial and eukaryotic cells, it is difficult to say 
how each putative target contributes to overall clearance. With this in mind, it may not be 
appropriate to refer to TZ as an EP inhibitor only. One of the major pieces of evidence 
supporting TZ’s role as an EP inhibitor is its increased efficacy against intracellular bacteria; 
a hypothesized “self-concentrating” effect inside macrophages. This is often explained by EP 
blockage, which would lead to an increase in intracellular concentration of the drug [72, 86]. 
However, this has not been shown directly. On the other hand, it has also been hypothesized 
that TZ is able to stimulate the macrophage itself and increase its microbicidal capacity [86]. 
In support of this, TZ has been implicated in the increased acidification of the phago-
lysosome (unpublished data by Elsa Anes’s group, University of Lisbon, Lisbon, Portugal). 
This macrophage stimulation could explain the contribution of TZ to combination treatment 
with RIF just as well as the blockage of EPs, and the overall killing of bacteria is likely due 
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to both of these factors. In the end, more cell biological experiments should be preformed to 
accurately determine where TZ’s antimicrobial capacity is rooted.  
 
5.4 Methodological considerations 
5.4.1 Optimization of primary macrophage culture 
Macrophages are known to be heterogeneous cells, both in morphology and function 
[162]. During pilot experiments in macrophage culture, the cell morphology we saw was not 
that of typical primary murine macrophages, which tend to be more rounded with irregular 
projections [163]. Instead, our macrophages were elongated and more fibroblast-like when 
plated on cell-culture treated dishes. Interestingly, this was not the case on non-treated dishes, 
where they looked more like typical macrophages. Initially, we were concerned that this 
could be due to incomplete differentiation of the cells. However, the phenotype did not 
change when we varied the source of M-CSF from recombinant cytokine to L929 conditioned 
media. In addition, these elongated cells displayed typical macrophage characteristics, such 
as the ability to efficiently phagocytose NPs and to show positive labeling for CD14 (Figure 
4.5 and 4.6). 
In comparison to similar experiments in the literature, where 10-20 ng/ml of the 
growth factor M-CSF is common, we have been using relatively high levels of M-CSF (40 
ng/ml) for the CFU time-kill assay. Reducing this value clearly changed the morphology of 
the cells to a more rounded shape, which could explain why our cells appeared so elongated. 
In addition, the higher levels of M-CSF increased the readings obtained from the CCK assay 
after six days (Figure 4.3). This increase could either be due to cell proliferation or cell 
activation, both of which have been associated with the effects of M-CSF [164].  
In addition to plastic-ware surface treatment and concentration of M-CSF cytokine in 
the media, macrophage morphology can be affected by plating density [165]. This could also 
explain the differences we saw on treated dishes compared to non-treated dishes (Figure 4.4), 
as the non-treated dishes in the images were sparsely populated compared to the treated 
dishes. In other words, macrophages are very sensitive to their environments, and like in all 
cell culture, lab-to-lab variation is inevitable. This makes it all the more important to keep all 
the accessible parameters as reproducible as possible and to be detailed about documenting 
every technical aspect of the procedure. Taking this into consideration, we decided to 
continue using the high concentration of M-CSF, (40 ng/ml), in order to be able to make 
comparison with previous results more valid and maintain reproducibility, especially 
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considering that the cells showed classic macrophage characteristics at this concentration of 
M-CSF.  
 
5.4.2 Establishing a luciferase assay 
The CFU time-kill assay has long been the ”golden standard” in microbiology for 
quantification of bacterial loads. Among its advantages are its simplicity and its high 
sensitivity for even minute quantities of bacteria. In addition, this method yields absolute 
numbers of bacteria, and only the viable (non-dormant) ones will form colonies, allowing for 
the exclusion of debris and non-viable bacteria [166]. However, this method also has several 
inherent drawbacks. First of all, quantification relies on manual counting of visible colonies, 
which can often clump together, making it difficult to distinguish one CFU from a small 
cluster of CFUs. BCG colonies also require up to three weeks before they can be counted, 
which together with 9 days of in vitro treatment makes each experiment take a month before 
any results are obtained. Further, colonies vary in size, and very small ones can easily be 
missed. Lastly, the wide range of detection relies on dilutions of the sample, which often fail 
to follow a linear relationship.  
In an attempt to increase the objectivity of in vitro BCG quantification following 
treatment with drugs, we attempted to establish a new protocol using firefly luciferase. This 
would not only give an unbiased reading of relative bacterial numbers, but it would also give 
results on the same day as bacteria are lysed, making the quantification quicker. When 
plating CFUs for BCG, two to three weeks are required before colonies become visible. With 
the luciferase quantification, sample processing is reduced, and results can be read 
immediately. However, unlike CFU quantification, the luciferase assay requires expensive 
reagents and specialized equipment.  
Luciferase quantification is classified as a bioluminescence assay. As a rule, 
bioluminescence produces a weaker signal, and fluorescence is often preferred in its place. 
However, unlike fluorescence, bioluminescence has very little background, which makes it 
more sensitive to weaker signals [167]. In addition, the luciferase enzyme does not require 
any post-translational modification and can therefore emit luminescence as soon as it is 
produced. Its half-life is also very short in cells, lasting approximately 3 hours after 
translation [168] This means that unviable bacteria will not be detected, which can be a 
problem with fluorescently labeled bacteria. 
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Before we could implement the new method, it had to be directly compared to CFUs. 
The luciferase assay has been used for quantifying mycobacteria by others, with a linear 
correlation to CFUs [169]. Similarly for us, parallel CFU and luciferase experiments using 
cells infected with BCG-lux showed that the traditional CFU method had a strong linear 
correlation with the luciferase assay (R2=0.998), although CFU values were consistently 
higher (Figure 4.9). This could be due to the fact that the luciferase assay requires more 
processing, which can lead to the loss of some sample material. 
One important aspect in the establishment of the luciferase bacterial-quantification 
was to explore the limit of detection. High sensitivity is one of the important strengths of the 
CFU method, as one can technically measure reduction in CFUs down to a single colony. We 
were concerned that the luciferase assay would not be sensitive to low numbers of bacteria, 
which we regularly obtain in killing experiments. Pilot experiments using BCG-lux in liquid 
culture were discouraging, as the lowest amount of bacteria that could be detected over 
background was an OD600 of 0.05, corresponding to 5x106 CFU. However, by increasing the 
concentration of the bacterial lysate by a factor of 50, we were able to go well below this 
limit, with the least amount of bacteria detected over background corresponding to 1300 
CFU, a level rarely reached by our time-kill assays.  
During the establishment of the protocol, an important aspect was the lysis of infected 
macrophages. Lysis of macrophages was carried out in the same way as for plating by CFU, 
but the extracted bacteria were in turn lysed to release all intracellular luciferase. A concern 
during pilot luciferase assay experiments was to ensure complete lysis of these bacterial cells, 
which is why samples were vortexed and sonicated twice during processing. Another concern 
was to remove as much as possible of the supernatant from macrophage lysis. If any of this 
supernatant were to carry over, it could dilute the sample, causing it to produce a lower 
signal. To avoid this as much as possible, macrophage lysate was spun down twice, and as 
much supernatant as possible was removed without disturbing the bacterial pellet. It remains 
to be seen, however, if this method can be reliably and reproducibly applied to the 
exploration of TZ and RIF combination treatment in vitro. 
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6 Conclusions 
TZ is now beyond patent protection [85], and with its background in compassionate 
use, has been suggested for global trials against human TB [155]. However, it has been 
emphasized that patients treated with TZ should be screened for signs of cardiotoxicity before 
and during treatment. The results in this thesis indicate that the high concentrations of TZ 
needed to treat mycobacterial infection are toxic when administered as free drugs in both in 
vitro and in vivo models of TB. However, by encapsulating TZ in biodegradable PLGA NPs, 
these toxic side-effects can be greatly reduced. If TZ’s toxicity is overcome, its addition to 
the traditional anti-TB regimen for human patients could be beneficial in several respects. 
First of all, the pleiotropic nature of TZ makes it less likely for any bacteria to become 
completely resistant to this drug. Furthermore, not only may TZ play a role in potentiating 
RIF efficacy, as shown by us in the zebrafish model and van Soolingen et al. in the mouse 
model [85], but it may also improve INH efficacy, as shown by Dutta et al. [89] at 3-fold 
lower concentrations of TZ than those used here for the potentiation of RIF. If TZ does 
indeed interact synergistically in humans with INH and RIF, two of the most potent anti-TB 
drugs, its addition to the traditional anti-TB regimen could contribute to shortening treatment-
time [53]. Together with TZ’s direct activity against both resistant and non-resistant bacteria 
[74, 76], this treatment-shortening effect could indirectly reduce patient non-compliance. In 
addition, encapsulating TZ in polymeric drug-carriers such as PLGA could not only reduce 
toxicity and facilitate local delivery, but also limit the frequency of drug administration due 
to sustained release of the drug from the NP. Taken together, these measures would both 
improve patient compliance and thereby help prevent the development of bacterial drug 
resistance in the first place. 
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7 Future perspectives 
7.1.1 Further nanoparticle optimization  
While we have conducted some optimization already, there are several aspects that 
can be tuned in NPs in order to more efficiently deliver drugs to their target sites. For 
instance, NP hydrophobicity and degradation time can be adjusted by varying the ratio of 
PLA to PGA in the PLGA copolymer formulation [124]. Chemical modification of PLGA 
end-groups can also increase or reduce degradation time of the polymer. For instance, PLGA 
that has terminal esters, as opposed to free, uncapped carboxylic acid has a longer 
degradation time in vivo [170]. Further, increasing the molecular weight of the copolymer can 
also decrease the rate of degradation; PLGA with a molecular weight of 10 kDa degrades 
twice as fast as PLGA with a molecular weight of 20 kDa [171]. A longer degradation time 
means that the drug encapsulated is released more slowly, potentially leading to more 
efficient TB therapy. Another possible improvement to the combined administration of RIF 
and TZ is to co-encapsulate the two drugs in the same NP [116]. This approach has been tried 
using another EP inhibitor, verapamil, by encapsulating it in PLGA NPs together with the 
cancer drug vincristine sulfate in an attempt to fight MDR in cancer cells [172]. However, 
this necessitates a relatively high loading of both drugs in the NP, which can be difficult to 
achieve if the drugs compete for encapsulation, especially since RIF and TZ have different 
degrees of hydrophobicity.  
 
7.1.2 The role of eukaryotic efflux pumps 
As briefly mentioned earlier, EPs are not just present in bacteria but are also common 
in eukaryotic cells. Here they have a similar function in that they pump out harmful 
substances from the cell [173]. In cancer cells, drug efflux is also closely associated with a 
drug resistant cell phenotype. For example, in cancer cells over-expressing P-glycoprotein 
(an ABC transporter), TZ is able to inhibit efflux of chemotherapeutics [174, 175]. In 
addition to blocking bacterial EPs, TZ has the potential to block these eukaryotic pumps. 
Macrophages have a lot less of the P-glycoprotein, but have several others EPs that could 
potentially be blocked by TZ [176]. If this is the case, TZ against intracellular bacteria could 
be concentrating not only at the bacterial level, but also the macrophage level, as suggested 
by Crowle et al. [72]. 
We have already initiated the process of exploring this question by high-pressure 
liquid chromatography coupled to mass spectrometry (HPLC-MS). For our application, this 
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method can separate TZ or RIF from cell lysates by HPLC and quantify the amount of 
intracellular drug by MS. Using this technique, we hope to quantify whether or not RIF (and 
TZ itself) can be concentrated in cells in the presence of the EP inhibitor TZ. 
 
7.1.3 Alternative combinations of efflux pump inhibitors and antibiotics 
Even if EP inhibition is central to TZ’s function, it is important to remember that EP-
mediated extrusion of drugs may be one of several mechanisms contributing to phenotypic 
resistance. Combination therapy using antibiotics and EP inhibitors may therefore only be 
efficient in those cases where efflux plays a major role [54]. In addition, even if pumps are 
promiscuous, if the antibiotic used for treatment is effluxed by a different pump than the one 
being blocked, it may still not have an effect in improving treatment. It follows that there is a 
need to explore the specific relationship between different pumps and their antibiotic 
substrates, as well as the EP inhibitors that interfere with their mechanism of action. If a 
given EP extruding a given antibiotic is not affected by TZ for instance, other compounds 
exist that can take TZ’s place in that they have been shown to block efflux, such as verapamil 
or piperine or derivatives of these [161]. Apart from varying the type of EP inhibitor used, it 
would also be interesting to explore the potentiation of INH therapy, which according to 
Dutta et al. [89] requires only 10 mg/kg of TZ to achieve a significant improvement in 
comparison to INH monotherapy in vivo, a three-fold lower dose than what was needed to 
improve RIF therapy in vivo [85]. 
 
7.1.4 Thioridazine and mycobacterial resistance 
TZ has been used against both genetically resistant and susceptible M. tb in bacterial 
culture [76] and inside macrophages [74, 161]. In addition, TZ has been shown to reduce 
macrophage-induced phenotypic resistance to INH and RIF using a 48-hour treatment of TZ 
at 2 µg/ml in vitro [161]. It would be interesting to explore TZ’s effect against phenotypic 
resistance further in vivo. For example, experiments could be carried out in the zebrafish 
model, by exposing infected larvae to low levels of RIF in a bath, in theory leading to 
induced phenotypic resistance to RIF. This could be followed by treatment with RIF and TZ, 
or a higher dose of RIF alone, in order to compare their relative efficiency. This would give 
an insight as to whether or not TZ contributes to fighting phenotypic resistance in vivo. 
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8 Appendix 
8.1 Supplementary methods 
8.1.1 Poly-L Lysine coating  
Coverslips (14 mm) were washed with 96% ethanol and lens paper to remove grease. 
For coating, 0.01% poly L-lysine (average molecular weight 150-300 kDa; Sigma-Aldrich, 
St. Louis, MO, USA) solution in water was prepared from a 10x stock. This was sterile 
filtered through a 0.2 mm filter and poured into a petri-dish. The coverslips were placed 
floating on this solution for 5 minutes using a pair of  sterile tweezers, and washed by dipping 
it in autoclaved milliQ water three times, minding which side has the coating. The coated 
coverslips were placed in a 12-well plate, and left to dry at RT overnight under and UV-light 
for sterilization. To store the coated coverslips, a lid was secured in place with parafilm. The 
remaining poly L-lysine solution was stored at +4 °C. 
 
8.1.2 Rotifer culture  
Rotifers were cultured in 14 L buckets in 2% salt water with circulation of oxygen 
and daily feeding with pasteurized microalgae (Reed Marine culture, Campbell, CA, USA). 
Rotifers were harvested and kept in 2% salt water for up to one week at 4°C. Before feeding 
larvae, rotifers were strained using a 70 µm cell strainer and washed with embryo water to 
remove all salt water. The rotifers were then re-suspended in embryo water and a few drops 
were added to the plates with larvae. Any remaining rotifers were removed when embryo 
water was changed. 
 
8.1.3 CFU time-kill assay using M. tb and primary human macrophages 
The following procedure was carried out by our collaborator David Pires, working in 
Elsa Anes’s group in Lisbon, Portugal. Primary human monocyte-derived macrophages were 
isolated and differentiated for 7 days with 20ng/ml M-CSF. On the day of infection, M. tb 
strain H37Rv was processed and added to cells at an MOI of 1 for 3 hours, followed by 
washing to remove extracellular bacteria. Treatment media was prepared with PLGA-RIF 
NPs at 25 and 50 µg/ml, which corresponds to 8 and 16 µg/ml free RIF, and PLGA-TZ NPs 
at 4.7 and 9.4 µg/ml, which corresponds to 1.25 and 2.5 µg/ml in free drugs. Treatment 
duration was 3 hours, followed by another wash. Bacterial load was quantified by CFU after 
3 hours (before treatment), and on days 1, 3, 5 and 7 post-infection. 
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8.2 Supplementary results 
 
Table 8.1: Summary of toxicity indicators recorded in 6 day-old zebrafish larvae treated with free TZ or 
encapsulated PLGA-TZ. All indicators were recorded at 4 dpt (6 dpf). (n= 6, 13 and 6 for free, NP and mock 
respectively) 
 
  Edema 
(+/-) 
Swim bladder inflation 
(+/-) 
Yolk discoloration 
(+/-) 
Survival  
(%) 
Free TZ (5/1) (0/6) (3/3) 40 
PLGA-TZ NP (2/11) (9/4) (2/11) 100 
Mock (1/5) (4/2) (1/5) 100 
 
 
 
 
Figure 8.1: Results from CFU time-kill assay using M. tb strain H37Rv and human primary macrophages, 
carried out by our collaborator David Pires from Elsa Anes’s lab in Lisbon, Portugal. Concentrations of RIF are 
given in weight of NPs of 25 and 50 µg/ml, which corresponds to 8 and 16 µg/ml free RIF. Concentrations of 
TZ are given in free drug weight.  
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  (days)	  
Control	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  25	  +	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  +	  PLGA	  TZ	  2.5	  PLGA	  RIF	  50	  +	  PLGA	  TZ	  1.25	  PLGA	  RIF	  50	  +	  PLGA	  TZ	  2.5	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8.3 Supplementary recipes 
8.3.1 7H10 agar plates 
The following was taken from [102]. Dissolve 19 mg 7H10 Difco Middlebrook 7H10 agar 
powder and 10 ml 50% glycerol in 900 ml sterile milliQ water. Autoclave this solution, and 
after it cools, add 10% OADC and 50 µg/ml Hygromycin. Fill in bacterial culture dishes 
under sterile conditions. Allow plates to cool and pack in sealed plastic bags, bottom-side up. 
Keep plates at 4 °C for up to two months, protected from light. Warm plates to 37°C before 
plating bacteria on them. 
 
8.3.2 ADC/OADC growth supplement 
ADC/OADC growth supplement are essential to the growth of slow-growing mycobacteria. 
Both of these contain sodium chloride to ensure osmotic equilibrium, albumin, which binds 
to toxic agents in the media, dextrose (glucose), an energy source for the bacteria and catalase 
which catalyzes the removal of hydrogen peroxide. In addition, OADC also contains oleic 
acid, a long chain fatty acid important to mycobacterial metabolism [177]. The following 
recipe is taken from [112]. Add 4.5 g NaCl, 25 g BSA, 10 g dextrose and 15 mg catalase 
to 400 ml sterile milliQ water under stirring at RT. Fill up with sterile milliQ water to a 
final volume of 500 ml, and adjust pH to 6.8-7.0 with 1 M NaOH. Sterilize by using a 
0.22 µm filter. Store up to 1 month at 4 °C. 
 
8.3.3  Tricaine stock solution 
The following was adapted from [102]. For 100 ml tricaine stock solution, 400 mg Tricaine 
methanosulfonate MS-222 (Argent laboratories group Inc., Redmond, WA, USA) was 
dissolved in 97.9 ml water and 2.1 ml 1M TrisCl (pH 9). The solution was adjusted to pH 7.4.  
For sedation, add 300 µl of the stock solution to 5 ml embryo water, giving a final 
concentration of 226 µg/ml tricaine. Do not leave the embryos for more than half an hour in 
this solution, as they will eventually die. 
 
8.3.4 Zebrafish embryo water 
The following was taken from [102]. For 100 ml embryo water, mix 1.0 ml Hanks' stock 
solution #1, 0.1 ml Hanks' stock solution #2 , 1.0 ml Hanks' stock solution #4, 1.0 ml Hanks' 
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stock solution #5 and 1.0 ml Hanks' stock solution #6 in 95.9 ml water. Adjust pH to 7.2 
(approx.10 drops 1 M NaOH) and autoclave or sterile filter. Can be stored indefinitely at 4°C 
 
8.3.5 Hanks’ stock solutions  
The following was taken from [102]. 
 
Stock #1: 
8.0 g NaCl 
0.4 g KCl 
100 ml H2O 
Stock #2: 
0.358 g Na2HPO4 anhydrous 
0.60 g KH2PO4 
100 ml H2O 
Stock #4: 
0.72 g CaCl2 
50 ml H2O 
Stock #5: 
1.23 g MgSO4·7H2O 
50 ml H2O 
Stock #6: 
0.35 g NaHCO3 
10 ml H2O 
Store indefinitely at 4°C. 
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